Role of dietary fat and supplementation in modulating neurodegenerative pathology in two animal model systems by Maulik, Malabika
ROLE OF DIETARY FAT AND SUPPLEMENTATION IN MODULATING
NEURODEGENERATIVE PATHOLOGY IN TWO ANIMAL MODEL SYSTEMS
By
Malabika Maulik, B.S, M.S.
A Dissertation Submitted in Partial Fulfillment of the Requirements
for the Degree of
Doctor of Philosophy
in
Biochemistry and Neuroscience
University of Alaska Fairbanks
December 2018
APPROVED:
Abel Bult-Ito, Committee Co-Chair
Barbara E Taylor, Committee Co-Chair
Lawrence Duffy, Committee Member
Thomas Kuhn, Committee Member
Kriya Dunlap, Committee Member
Thomas Green, Chair
Department of Chemistry and Biochemistry 
Leah Berman, Interim Dean
College of Natural Sciences and Mathematics
Michael Castellini, Dean of Graduate School
Abstract
Neurodegenerative disorders are progressive conditions that worsen over time and results in death 
of neurons. Parkinson's disease (PD) is a prevalent example of one such age-related disease, which 
is characterized by movement disorder (ataxia) and/or cognitive disability (dementia). 
Pathologically, PD is characterized by a toxic accumulation of α-synuclein protein in the midbrain 
leading to degeneration of the dopaminergic neurons. The etiology of PD is intricate, and the cause 
is attributed to genetic mutations and environmental factors like insecticides or heavy metals. 
Moreover, treatment options are limited and often aimed at treating the symptoms rather than the 
actual disease progression. Using the nematode model of Caenorhabditis elegans, I examined the 
effect of Alaskan bog blueberry (Vaccinium uliginosum) on a-synuclein overexpression and how 
such indigenous natural treatment can modulate key molecular targets like sirtuins, which are 
proteins involved in regulating cellular processes including aging, death and their resistance to 
stress. The impact of extrinsic factors like dietary fat on PD pathology has been sparsely explored 
and the molecular basis of such changes is not known. Through my thesis research, I also further 
investigated the influence of fat metabolism on key hallmarks of PD: a-synuclein overexpression 
and dopaminergic degeneration in the nematode model. Finally, I studied the interaction of dietary 
fat (normal, low and high fat) and Alaskan blueberry supplementation on metal induced 
neurotoxicity model of Mus musculus. Our results highlight the beneficial properties of Alaskan 
blueberries in combating proteotoxic stress and inflammation in both animal models. They also 
reiterate the benefit of low fat diet, on its own or in combination with supplementation in 
improving several PD-like molecular features and how consuming high fat can mask such health 
promoting outcomes. The current thesis work therefore, provides a foundation for further 
i
exploration of neurobiological changes associated with consumption of natural products and 
different diets and how such alterations can be extrapolated to humans.
ii
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Chapter 1: General Introduction
Neurodegeneration Parkinson's disease (PD) is one of the most commonly occurring age- 
related neurodegenerative disorders. Seven to 10 million individuals are affected by PD worldwide 
[1]. The mean age of onset is around 60 years, where 1% of all individuals over the age of 60 and 
4% of those over 80 exhibit PD symptomology. Pathophysiologically, PD is characterized by the 
continuous and aggravated loss of dopaminergic neurons in the substantia nigra pars compacta 
(nigrostriatal pathway) area of the brain [2]. At the cellular level, intra-cytoplasmic inclusions of 
misfolded α-synuclein protein result in formation of Lewy bodies and dystrophic Lewy neurites in 
neurons [3, 4]. This results in loss of dopaminergic neurons causing motor impairments, including 
tremors, hypokinesia, bradykinesia, rigidity, and postural instability [5-7]. Festination, speech and 
swallowing disorders and handwriting changes constitute the other identifiable motor deficits [6, 
8]. Due to the neuronal loss in both central and peripheral nervous systems, patients often 
experience several non-motor symptoms such as anxiety, depression, memory loss, and olfactory 
deficits [9, 10]. Genetic (familial) and environmental (sporadic) triggers have emerged as two 
major factors in PD pathophysiology, with environmental exposure accounting for over two-thirds 
of all reported cases [11-14]. Susceptibility to both sporadic and familial types of PD is linked to 
polygenic factors. Some of the implicated genes include a-synuclein, Leucine rich repeat kinase 2 
(LRRK2), pink-1, parkin 2 (PARK2), protein deglycase DJ-1, and others. For example, a mutation 
in the glucocerebrosidase (GBA) gene, which codes for an enzyme essential for metabolism of 
lysosomal substrates, is linked to the pathogenesis of sporadic PD [15]. Similarly, a mutation in 
the ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), an enzyme involved in the removal and 
recycling of ubiquitin molecules from degraded proteins, and ligation of ubiquitin to proteins to 
mark them for degradation, has been linked to the early-onset of familial PD [2]. The identification 
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of these and other genes, and the discovery that certain toxins such as MPTP (1-methyl-1, 2, 3, 6- 
tetrahydropyidin) [16], 6-OHDA (6- hydroxy dopamine) [16], and rotenone [17] lead to PD 
symptoms, has informed the development of genetic and toxin-induced PD models [13, 16, 18, 19] 
and resulted in a better understanding of disease etiology, pathology, and molecular mechanisms 
[20, 21].
1.1 Caenorhabditis elegans and Mus musculus models of Parkinson's Disease
1.1.1 Nematode Caenorhabditis elegans
Invertebrate models such as Caenorhabditis elegans are useful in investigating the 
molecular mechanisms of PD pathology [22]. These models promote the studies of PD-associated 
molecular signaling pathways and first-round screening that can be further examined in 
mammalian models [23]. The nematode C. elegans is a useful model organism for studying healthy 
and abnormal neuronal aging, including cellular pathologies of PD. C. elegans share many 
conserved cellular pathways and mechanisms with mammals, including humans [24-26]. These 
cellular pathways can be genetically manipulated using RNA interference (RNAi) by gene-specific 
feeding bacteria that deliver RNA for gene specific interference [27], which enables rapid 
screening of target genes [28, 29]. RNAi screening is an important tool for predicting pathogenic 
mechanisms before moving to complex organisms for further investigation [28, 30, 31]. Despite 
major anatomical differences from humans, the C. elegans nervous system consists of a 
circumpharyngeal nerve ring and contains key cellular and molecular features of mammalian 
neurons, including conserved neurotransmitter systems (dopamine, GABA, acetylcholine, 
serotonin, etc.), receptors, axon guidance molecules, ion channels, and synaptic features [32]. 
Although a-synuclein is not endogenous to C. elegans, expression of this human PD-associated 
protein in C. elegans dopaminergic (DA) neurons results in age-dependent neurodegeneration [33- 
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35]. Moreover, most familial PD genes such as PINK1, PARK, DJ-1, and LRRK2 have at least 
one C. elegans homolog [36-38]. Hermaphroditic C. elegans have 302 neurons, of which eight 
(ADEL, ADER, CEPDL, CEPDR, CEPVL, CEPVR, PDEL, and PDER) are dopaminergic such 
as those implicated in PD in humans [39]. This has led to creation of transgenic models with 
fluorescently labelled dopaminergic neurons to examine the effect of environmental factors on 
neuronal health [40]. In addition, four dopamine receptors (DOP-1, DOP-2, DOP-3, and DOP-4) 
have been identified in C. elegans, including homologs of each of the two classes of mammalian 
dopamine receptors (D1- and D2-like) [41]. C. elegans have low maintenance costs, and their 
shorter lifespan (2-3 weeks) reduces the time needed for each experiment. These advantages make 
C. elegans a valuable model system for genetic and chemical screening, and pre-clinical research. 
In contrast, the limitations of a C. elegans PD model include a lack of defined organs, including 
the complex brain structure seen in humans and, therefore, the inability to recapitulate the same 
set of complex interactions involving various brain cells and tissues seen in human PD patients 
[42]. In addition, impermeability of the cuticle and inability of intestinal cells to absorb certain 
chemicals may require high exposure doses to affect the animal's physiology [30, 42]. Despite 
these limitations, C. elegans have proven useful in aging research [42] and numerous studies have 
used nematodes to investigate the cellular mechanisms associated with PD [22].
1.1.2 House Mouse (Mus Musculus)
PD models of house mouse (Mus musculus) models have been established to critically 
understand PD pathology and to investigate new therapeutic strategies [43]. These models display 
many of the clinical features of PD such as the Lewy body formation, loss of dopaminergic neurons 
in substantia nigra [44-46], disease progression associated with age, motor dysfunction, and non­
motor symptoms including cognitive decline, autonomic dysfunction, depression, and hyposmia 
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[47, 48]. Over the last decade, several mouse models have been generated with genetic mutations 
that have been associated with familial PD [48]. These models have provided valuable insights in 
understanding the impaired cellular mechanisms that contribute to the molecular pathology of the 
disease. However, the available models do not exhibit the considerable extent of 
neurodegeneration and related behavioral phenotypes [49]. This includes failure to reproduce the 
dopaminergic cell loss in the substantia nigra or locus coeruleus [50-52]. This limitation of genetic 
models can be addressed by models with toxin-induced dopaminergic neuron loss in these regions. 
Several pharmacological and neurotoxic rodent models have been developed that feature the major 
symptoms of human PD including rigidity, tremor, postural instability, and slowness of movement 
[48, 53, 54]. PD mouse models closely mimic human PD pathology but none present all the 
pathological features, and therefore, only partial knowledge can be acquired from studies using 
these models. Despite these shortcomings, rodent models are still considered to be very useful in 
understanding the underlying mechanisms and development of therapies to treat PD.
1.2 Genetic PD models of C. elegans and M. musculus
1.2.1. a -Synuclein
a -synuclein is a small, presynaptic cytoplasmic protein, which is highly conserved in 
vertebrates and has been implicated in PD and other synucleinopathies [55]. Studies suggest that 
a-synuclein may be important for synaptic transmissions [56]. The a-synuclein gene, SNCA, is 
causatively related to PD and its mutation was the first gene to be linked to the disease [18]. 
Mutations in SNCA, including rare point mutations as well as duplications and triplications of 
wild-type a-synuclein in the form of A30P, A53T, and E46K cause familial forms of PD in humans 
[11, 57, 58].
4
C. elegans do not have an α-synuclein homolog. Thus, to study the pathogenicity of a- 
synuclein overexpression and aggregation in PD, several transgenic C. elegans strains with human 
a-synuclein have been created. These strains are particularly useful for studying the toxicity of 
protein aggregates, and cellular and behavioral abnormalities [35, 59]. Strains OW13 ([unc-54p::a- 
synuclein::YFP + unc-119(+)]), NL5901 ([unc-54p::a-synuclein::YFP+unc-119(+)]), and DDP1 
(uonEx1[unc-54p::a-synuclein::CFP + unc-54::a-synuclein::YFP(Venus)] express a-synuclein in 
body wall muscle cells [59, 60]. In these strains, the human a-synuclein gene is fused to yellow 
fluorescent protein (YFP) and expressed under the control of the unc-54 promoter [35, 59, 60]. 
These strains have been used to study a-synuclein aggregation, changes in movement, animal 
behavior and genes that modulate these and other PD-related hallmarks. In addition to strains that 
overexpress a-synuclein in body wall muscle cells, strains that overexpress wild-type or mutant 
(A53T) human a-synuclein in dopaminergic neurons have been generated by multiple research 
groups [33, 34, 61, 62]. In these models, the dopamine transporter promoter dat-1 is fused to green 
fluorescent protein (GFP), following co-expression of wild-type or mutant (A53T) a-synuclein 
and GFP. In C. elegans expressing a-synuclein (wild-type or mutant) in dopaminergic neurons, 
neuronal abnormalities, accumulation of aggregates and cell loss were observed, typically in an 
age-dependent manner [33, 34, 61, 62].
In mice, the transgenic models of a-synuclein knockout or expression of the wild-type [63] 
and mutant (A53T and A30P) forms [64, 65] have been generated to study the normal 
physiological function of the protein. Apart from that, a-synuclein overexpression models of mice 
exhibits neurodegeneration which is dependent on the promoter used to express the transgene. The 
accumulation of a-synuclein in these models leads to disruption in the functioning of dopaminergic 
neurons [65, 66]. Behavioral deficits have been observed in both the A30P and A53T mice [67- 
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69]. However, there was no cell loss in the substantia nigra when the transgene was expressed with 
both the mouse and hamster prion protein promoter [70-73]. Similarly, mice with the PDGF-β 
promoter showed loss of terminals and dopamine (DA) levels in the striatum but no cell loss [66]. 
Transgenic mice that over expressed α-synuclein A53T in the dopaminergic neurons featured 
motor impairment, degeneration of neurons in the midbrain and decreased levels of DA [74, 75]. 
In wild-type mice, a single striatal or hind limb intramuscular injection of a-synuclein led to typical 
Lewy-body pathology, progressive loss of dopaminergic neurons in the midbrain and reduced DA 
levels in the striatum accompanied by motor deficits [76-78].
1.2.2 LRRK2 and PINK1
In PD patients, mutations in the multi-domain protein leucine-rich repeat kinase 2 (LRRK2) 
are the most common genetic risk factors for both familial and sporadic PD, accounting for 4% of 
familial and 1% of sporadic PD across all populations [79]. Mutations are prevalent within the 
GTPase (R1441C/G) and kinase (G2019S) domains of LRRK2 [79]. Mutations in the gene a 
PTEN-induced kinase 1 (PINK1) leads to another form of PD called PARK6 [80].
In C. elegans, the lrk-1 gene is homologous to mammalian LRRK1 and LRRK2, human and 
mouse leucine-rich repeat kinases, respectively. lrk-1 mutants have been used to study pink-1, 
homolog of the human PINK1 suggesting that LRK-1 and PINK-1 act antagonistically in stress 
response and neurite outgrowth [37]. PINK-1 mutation in worms resulted in reduced mitochondrial 
cristae length and heightened paraquat sensitivity. These losses of function were suppressed upon 
deleting the lrk-1 gene [37]. In other studies, human wild-type and mutant G2019S and R1441C 
LRRK2 have been overexpressed in dopaminergic neurons of C. elegans under the control of the 
dopamine transporter dat-1 promoter co-injected with dat-1p::GFP to generate transgenic lines 
[62, 81]. Overexpression of these LRRK2 proteins caused age-dependent degeneration of 
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dopaminergic neurons, behavioral deficits, locomotory dysfunction, and reduced DA levels in 
transgenic C. elegans [62, 81].
LRRK2 knock-out models of mice exhibited accumulation of a-synuclein but no functional 
loss of dopaminergic neurons in the midbrain [48, 52]. However, over expression of G2019S 
LRRK2 in mice resulted in mild degeneration of dopaminergic neurons in the substantia nigra 
[82]. Additionally, some studies also reported viral-vector based models of mutant LRRK2 [83], 
which demonstrated considerable neuronal loss compared to wild-type LRRK2. Similarly, PINK- 
1 knockout in mice on its own does not present any of the typical features of PD-like movement 
deficit and reduced DA levels [72, 84]. However, in PINK1 knock-out mice, overexpression of a- 
synuclein in the substantia nigra resulted in enhanced degeneration of dopaminergic neurons and 
higher levels of a-synuclein [85].
1.2.3 Parkin
Some autosomal recessive forms of familial PD are associated with mutations in Parkin 
(PARK2), an E3 ubiquitin ligase that is important for neuronal protein homeostasis [19, 86-88]. In 
C. elegans, the PARK2 homolog pdr-1 is an essential component in the degradation machinery 
during the response to proteotoxic stressors [89]. Specifically, pdr-1 was shown to play a role in 
the unfolded protein response (UPR) pathway, and co-expression of mutant a-synuclein A53T and 
truncated pdr-1 exacerbated mutant a-synuclein-induced toxicity in a UPR-independent way [89].
Several Parkin knockout mice have been generated by deleting different exons in the PARK2 
gene [51, 90-92]. Such mice exhibited motor deficits, age-dependent neuronal degeneration and 
reduced levels of DA in the striatum [93].
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1.2.4 DJ-1
In humans, the DJ-1 gene is mutated in 1-2 % of early onset PD [94]. Its functions include 
transcriptional regulation, antioxidant activity (particularly after toxic insults), chaperone activity, 
protease cleavage, and mitochondrial regulation [95].
C. elegans have two DJ-1 orthologs: djr-1.1, and djr-1.2; both encode a type of glyoxalase. 
In C. elegans, neuronal expression of DJR-1.2 in the head and ventral nerve chord neurons is 
elevated after exposure to acute manganese (Mn) [96] and djr-1.2 is protective against Mn-induced 
dopaminergic toxicity in an age-dependent manner [96]. The C. elegans djr-1.1, localizes to the 
intestine and plays a primary role in protecting animals from glyoxal-induced death [97].
Transgenic DJ-1 mouse models show loss of dopaminergic neurons in the vental tegmental 
area [98] and altered DA levels in the striatum [99, 100]. Also, another transgenic DJ-1 mouse line 
with a C57/BL6 background demonstrates age-dependent progressive neuronal loss in the 
substantia nigra [101].
1.3 C. elegans and M. musculus Toxin-induced Models of Parkinson's Disease
1.3.1 MPTP and 6-OHDA
In animal models of PD, exposure to toxins that cause an overload of reactive oxygen species 
(ROS) and disrupt the electron transport chain in mitochondria that leads to neuronal abnormalities 
and eventually cell death [102, 103]. The best studied neurodegeneration-inducing chemicals in 
both C. elegans and mice PD models are the toxins 6-hydroxy dopamine (6-OHDA) and 1-methyl- 
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [40, 48, 104-106].
MPTP was first identified as a PD-causing neurotoxin in humans in the 1980s after drug 
addicts in California inadvertently administered the agent present as a contaminant in synthetic 
heroin [107]. MPTP is lipophilic and can therefore cross the blood brain barrier. In the brain, it is 
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converted to 1-methyl-4-phenylpyridinium ion (MPP+) by glial monoamine oxidase B [108]. 
MPP+ inhibits complex I of the mitochondrial electron transport chain to induce mitochondrial 
dysfunction, impair autophagic degradation and ultimately cause neuronal loss [109]. In C. 
elegans, MPTP treatments selectively degenerate dopaminergic neurons [110, 111]. In mice, 
MPTP results in loss of dopaminergic neurons in both striatum and substantia nigra [112].
6-OHDA is a selective catecholaminergic neurotoxin; it has a chemical structure similar 
to DA but with the addition of a hydroxyl group that makes it toxic to dopaminergic neurons [21]. 
In PD research, the administration of 6-OHDA causes mitochondrial failure through inhibition of 
complex I of the mitochondrial electron transport chain. This leads to ATP depletion and elevated 
oxidative stress, which ultimately results in dopaminergic neuron damage [40, 44, 111]. In C. 
elegans, 6-OHDA administration leads to the loss of GFP-labeled dopaminergic cell bodies and 
processes [40, 113]. Since 6-OHDA cannot cross the blood brain barrier, mouse models require a 
stereotaxic injection of this toxin in the mid-brain or striatum [114] causing progressive 
degeneration of dopaminergic neurons in these brain regions [115].
1.3.2 Insecticides and Herbicides
Rotenone (a broad-spectrum insecticide), paraquat (an herbicide), and benomyl (fungicide) 
have been used to induce PD-like pathology in both C. elegans and mouse models of PD [2, 22, 
48]. Both paraquat and rotenone trigger excessive ROS production in neurons, which leads to 
cellular damage [116-119]. Benomyl inhibits aldehyde dehydrogenase (ALDH), which detoxifies 
the DA metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). Benomyl-treated mice 
accumulate DOPAL and resemble mice with knockouts of the genes encoding ALDH1A1 and 2, 
a mouse model of aging-related PD. Thus, there are at least two mechanisms by which pesticides 
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can induce PD-like symptoms.
Rotenone delivered to mice through chronic intragastric or stereotaxic administration 
has been used to cause slow dopaminergic neuron loss [120, 121]. Similar to rotenone, paraquat 
administration in mice has been used to induce Lewy body formation in DA neurons [122]. C. 
elegans strains including BY250 (dat-1p:GFP), BZ555 (dat-1p:GFP), and UA57 ([dat- 
1p::GFP+dat-1p::cat-2]) can be exposed to these toxins to visualize and quantify abnormalities 
in neuronal morphology [120, 121, 123, 124]. Thus, both animal models have advantages for 
studying the cellular mechanisms and pathophysiology of PD.
1.3.3 Manganese
Mn is an essential transition metal required for growth, development and cellular homeostasis 
[125]. It is a co-factor for multiple enzymes such as Mn superoxide dismutase, pyruvate 
carboxylase, arginase, and glutamine synthetase, and can substitute for magnesium (Mg) in 
enzymatic reactions catalyzed by kinases [126]. However, inhaling toxic levels of Mn can lead to 
nasal and pulmonary inflammation, renal dysfunction, and neurodegeneration [127, 128]. For 
example, occupational exposure through Mn mining, steel manufacturing, and welding are linked 
to increased risk for parkinsonian syndrome commonly known as Manganism [129]. Specifically, 
exposure to toxic levels of Mn can cause oxidative injury in the substantia nigra, the loss of 
dopaminergic neurons and motor deficits such as tremor, rigidity, and bradykinesia [130, 131].
In C. elegans, extracellular dopamine was found to be responsible for oxidative stress and Mn- 
induced dopaminergic neurodegeneration [132]. Mn neurotoxicity has also been studied in genetic 
DJ-1 models of C. elegans exposed to Mn [96].
In mice, sub-cutaneous injections of manganese chloride have resulted in behavioral deficits and 
metal accumulation in the basal ganglia of the brain [133, 134]. Another study reported the loss of 
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dopaminergic cells in the substantia nigra due to chronic manganese exposure in mice [135]. Mn 
exposure also triggers mitochondrial dysfunction and neurodegeneration in the nigrostriatal region 
and microglial activation in transgenic mice models [136, 137].
1.4 Role of Diet in Parkinson's Disease
Environmental factors play an important role in the progression and etiology of PD [14]. 
Therefore, it is imperative to understand the role of diet in remission or exacerbation of the disease 
pathology and symptoms. Dietary fat which contributes to obesity and metabolic disorders, also 
plays an important role in causing neurodegenerative disorders [138, 139]. Epidemiological studies 
also refer to the possible link between consumption of high saturated fat and higher risk of 
developing PD [140, 141].
Disruption of fat metabolism can cause an obesity-like condition in a diverse range of 
multicellular organisms: C. elegans to mammals [142]. Fat metabolism in C. elegans includes 
an intricate and conserved gene network, which plays a role in food sensing and neuroendocrine 
signaling processes [143]. In nematodes, food sensing behavior is also controlled by a well 
mapped dopaminergic system, which is also a key network affected in PD [144]. Despite the 
lack of specific adipocytes, C. elegans shares common human homologues of genes that are 
implicated in obesity and metabolic disorders [143, 145]. In mammals, nuclear hormone 
receptors (NHRs) like peroxisome proliferator-activator receptor protein-alpha (PPARa) are 
often studied as drug target for lipid metabolism [146]. In C. elegans, one such receptor known 
as nhr-49 promotes fatty acid desaturation and beta-oxidation leading to 'high fat' accumulation, 
altered mitochondrial function and shortened lifespan [142, 147]. Like mammals, mutations in 
tub-1 (tubby homologue) leads to increased fat deposition and lifespan increase in C. elegans 
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[148]. Δ9 desaturases enzymes are present in organisms from yeast to humans and are important 
for energy metabolism and lipid synthesis [149]. Diets high in unsaturated fatty acids decrease 
expression of A9 desaturase and high carbohydrate consumption increases its expression [149]. 
In C. elegans, A9 desaturases are encoded by genes fat-5 and fat -7. RNAi for fat-5 and fat-7 
has reduced fat content in the nematodes [142]. C. elegans being a popular genetic model allows 
easy manipulation of these 'fat genes' using RNAi to create high and low fat content in the 
organisms. Moreover, fatty acid metabolism is known to be involved in stress resistance 
mechanisms and insulin signaling in the worm model [150]. Recently, such stress resistance 
mechanisms have been used to study the effect of aging and insulin signaling in C. elegans 
models of PD [62]. The models have been well developed to understand the symptoms of PD: 
a-synuclein overexpression, genetic mutations like A53T and LRRK2, and environmental toxin- 
induced dopaminergic neurodegeneration. Such models are also known to display phenotypic 
abnormalities that can be used as measure of aging, another key risk factor for PD [62]. 
Nematodes have emerged as a very popular in vivo model to study PD [22] and obesity [151]. 
However, no studies have yet investigated interactions of fat metabolism and PD-like pathology 
and cellular symptoms in this popular worm model.
In mice, high fat diets exacerbate the progression of PD-like symptoms by increased 
dopaminergic neurodegeneration in striatum and substantia nigra [152-154]. Other than worsening 
MPTP-induced dopaminergic loss, high fat diet also increases inflammation in mice characterized 
by elevated levels of cytokines and chemokines [153]. Also, genetic studies involving parkin 
suggest an association between fat and PD [155]. Lipid and cholesterol metabolism though highly 
debated may also play a key role in modifying pathogenesis of idiopathic PD [156, 157]. On the 
other hand, low fat diets or caloric restriction have demonstrated life span extending properties in 
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many organisms [158-161]. A low-calorie diet increased the stress response in neurons in in vivo 
models of neurodegenerative disorders [162]. Caloric restriction is also known to enhance 
cognitive function by promoting synaptic plasticity and upregulating neurotrophic factors like 
BDNF [159, 163]. In mouse models of PD, dietary restriction improves motor function, reduces 
oxidative stress and enhances mitochondrial function [164]. In another study with a toxin-induced 
model, such restriction implicated a role of glutamate homeostasis in improving PD pathology 
[165]. Most of the studies investigating fat manipulations have been done using MPTP mice 
models; other avenues in PD pathogenesis have been sparsely explored. Also, there are 
epidemiological studies that refute a relationship between fat and PD [166-169]. Therefore, the 
complex interaction between dietary fat and PD-associated pathology and behaviors warrants 
further investigation.
1.5 Role of Natural Compounds in Parkinson's Disease.
Consumption of a diet containing high amounts of fruits and vegetable has been linked to 
lower levels of age-related neurodegenerative diseases such as PD and Alzheimer's disease [170]. 
Dietary supplementation with naturally available products like blueberries, spinach, grapes etc. 
have high levels of anti-oxidants that can combat oxidative stress [171], which is a key 
phenomenon that occurs in aging and age-related disorders [172]. These foods contain a specific 
class of compounds known as 'polyphenols' which are known to play a therapeutic role in 
attenuating pathology of neurological disorders [170]. Polyphenols like resveratrol have been 
shown to reduce the loss of dopaminergic neurons, inflammation and oxidative stress in animal 
models of PD [173].
In C. elegans, several natural compounds have shown to improve symptoms of 
neurological disorders [174]. Extracts from the Indian plant Brahmi (Bacopa monieri) and a 
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traditional Chinese herb (Corydalis bungeana) have exerted protection in both transgenic and toxin 
induced models of C. elegans [144, 175, 176]. Blueberry polyphenols were also found to extend 
lifespan in C. elegans [177]. Indigenous Alaskan botanicals have consistently shown to contain 
higher levels of polyphenolic compounds (e.g., phenolic, anthocyanin and flavonoid) than other 
commercially grown, temperate species [178]. Alaskan plants produce a wide variety of secondary 
metabolites in response to adaptation to extreme Artic climate [178]. Interplay between these 
secondary metabolites of various plant species and molecular targets has been shown to have pro-
health and anti-aging effects [179]. A protein target is sirtuin 1-a histone deacetylase (sirtuin 1), 
which can impact the progression of age-related disorders by directly influencing the transcription 
machinery [180]. Polyphenols from grapes and tea interact with sirtuin 1 to reduce inflammation, 
promote neural plasticity and reduce cell death [181, 182]. Alaskan bog blueberries have been 
shown to inhibit inflammation in neuronal cell culture [183] and improve age-related 
mechanosensory deficits in C. elegans [179].
Quercetin (a flavonoid polyphenol found in many fruits and vegetables, notably apples) 
has been shown to reduce microglial activation in a MPTP-induced cell line [184]. Polyphenols 
such as baicalein [185], caffeic acid [186] and epigallocatechin gallate (EGCG) [187] conferred 
neuroprotection in various PD-like models. Blueberries (Vaccinium angustifolium) in particular 
improve object-recognition memory loss in aging rats [172] and improve memory in humans 
[188]. Blueberries also have been extensively investigated for their effect on cellular signaling and 
neurodegeneration [189, 190].
1.6 Research Objectives
The main objective of this thesis is to explore the complex interactions of diets and 
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supplements in the form of Alaskan bog blueberry polyphenols on PD-like symptoms in two 
animal model systems: C. elegans and M. musculus, through the completion of the following 
aims:
1.6.1 Aim I: Study the Role of Alaskan Bog Blueberries on a-synuclein Overexpression in a 
Transgenic C. elegans Model of PD.
This study aimed to examine the effect of Alaskan bog blueberry polyphenols on protein 
misfolding and motility defects in the nematode model. The research also aimed to understand 
the underlying molecular mechanisms influenced by these blueberry polyphenols and if such 
mechanisms involved sirtuin 1, a key histone deacetylase needed for cell growth and survival 
[180].
Previous studies show that Alaskan bog blueberries ameliorate age-related deficits and 
improve neuronal health in both in vivo and in vitro models [179, 183]. However, no studies 
have been conducted to understand the role of polyphenols from these endemic berries on 
protein-overexpression, a key feature of neurodegenerative disorders such as PD [3]. Moreover, 
dietary polyphenols have been found to mitigate age-related cellular damage by influencing cell 
signaling pathways mediated by sirtuin 1[191]. Based on these previous findings, I 
hypothesized: Alaskan bog blueberry polyphenols will reduce a-synuclein overexpression in a 
C. elegans model of PD through a sirtuin 1-mediated pathway. My experimental results will 
provide a better understanding of this indigenous botanical as a therapeutic option for 
overcoming age-related molecular stress, such as protein aggregation. They also will encourage 
future investigation of how phytochemicals can modulate pathways for cell survival in disorders 
of nervous system.
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1.6.2 Aim II: Silencing Fat Metabolism Genes in Parkinson's like Models of Caenorhabditis 
elegans.
This study aimed to explore the effect of genetic knockdown of four fat metabolism 
genes.nhr-49, tub-1 (high fat genes), fat-5, and fat-7 (low fat genes) on PD-like cellular symptoms 
(a-synuclein overexpression wild-type and A53T mutation and toxin-induced dopaminergic 
neurodegeneration) in C. elegans.
The effect of fat metabolism on aging and related pathologies like PD is poorly understood 
(refer to section 3). Based on the previous interactions, I hypothesized: silencing of low fat genes 
will increase lifespan, decrease protein overexpression, and rescue neuronal degeneration in C. 
elegans compared to knockdown of high fat genes. This study is first of its kind to investigate 
the interaction of fat metabolism, aging, and PD-like symptoms in C. elegans. The results 
will also encourage future studies to characterize the fat content and further decipher 
downstream molecular targets in the fat metabolic pathway in the nematode PD models.
1.6.3 Aim III: Complex Interaction of Dietary Fat and Alaskan Bog Blueberry Supplementation 
Influences Manganese Mediated Neurotoxicity and Behavioral Impairments.
This study is aimed at understanding the complex interaction between dietary fat and 
supplementation on metal-induced cellular and behavioral symptoms in a mouse model.
Several studies have highlighted the stand-alone effects of diets and phytochemicals on 
ageing endpoints (refer to section 3 and 4). The interactions of diet, supplement, and toxic metal 
exposure is not well understood. Based on the previous research, I hypothesized: Mice fed a low 
fat diet will perform better on the behavioral and biochemical endpoints compared to those fed a 
high fat diet. Attenuation of manganese-induced behavioral deficits by blueberry supplements will 
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be more pronounced in low fat diet groups. The results from this research will strengthen the 
association between obesity and neurodegeneration. They will also restate the benefits of 
consuming a low fat diet and how health-stimulating effects of supplements like blueberries can 
depend on the type of diet with which they are consumed.
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Chapter 2: Sir-2.1 Mediated Attenuation of α-synuclein Expression by Alaskan Bog Blueberry 
Polyphenols in a Transgenic Model of Caenorhabditis elegans
2.1 Abstract
Misfolding and accumulation of cellular protein aggregates are pathological hallmarks 
of aging and neurodegeneration. One such protein is α-synuclein, which when misfolded, forms 
aggregates and disrupts normal cellular functions of the neurons causing Parkinson's disease. 
Nutritional interventions abundant in pharmacologically potent polyphenols have demonstrated a 
therapeutic role for combating protein aggregation associated with neurodegeneration. The current 
study hypothesized that Alaskan bog blueberry (Vaccinum uliginosum), which is high in 
polyphenolic content, will reduce α-synuclein expression in a model of Caenorhabditis elegans 
(C. elegans). We observed that blueberry extracts attenuated α-synuclein protein expression, 
improved healthspan in the form of motility and restored lipid content in the transgenic strain of 
C. elegans expressing human α-synuclein. We also found reduced gene expression levels of sir-
2.1 (ortholog of mammalian Sirtuin 1) in blueberry treated transgenic animals indicating that the 
beneficial effects of blueberries could be mediated through partial reduction of sirtuin activity. 
This therapeutic effect of the blueberries was attributed to its xenohormetic properties. The current 
results highlight the role of Alaskan blueberries in mediating inhibition of sir-2.1 as a novel 
therapeutic approach to improving pathologies of protein misfolding diseases. Finally, our study 
warrants further investigation of the structure, and specificity of such small molecules from 
indigenous natural compounds and its role as sirtuin regulators.
Published as Maulik M, Mitra S, Hunter SC, Hunstiger M, Oliver Ryan S, Bult-Ito A & Taylor BE (2018) Sir-2.1 
mediated attenuation of α-synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of 
Caenorhabditis elegans. Scientific Reports. doi: 10.1038/s41598-018-26905-4.
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2.2 Introduction
Neurodegeneration can lead to a multitude of pathological conditions that primarily affects 
the nervous system 1,2. The debilitating conditions resulting from progressive degeneration and/or 
death of neurons can lead to impairments in movement, memory processing, affective behaviors 
and emotional functioning 3,4. Several such diseases are classified as protein misfolding diseases 
in which certain proteins become structurally abnormal and fail to fold into their normal 
configuration. In the misfolded state, these proteins can become toxic and disrupt normal cellular 
processes 5-8. One such protein is α-synuclein whose original function is vesicular transportation 
in the pre-synaptic terminal of neurons 9,10 Misfolding of α-synuclein leads to its over aggregation 
and accumulation 11,12. This is characterized by formation of small cytoplasmic a -synuclein 
inclusions in the neurons known as Lewy bodies, which is one of the key pathological hallmarks 
of Parkinson's disease 13. Similar molecular pathologies are also characteristic signatures of 
disorders like Lewy body dementia and multiple system atrophy 14-16. Despite significant strides 
in unraveling some of the cellular mechanisms contributing to these disorders, treatment strategies 
have been elusive. Development of new therapeutics are, therefore, of utmost public health 
priority.
There is substantial evidence that specific dietary regimen and plant-based 
supplementation is closely intertwined with the aging process and related disorders including 
neurodegeneration 17,18. Phytochemically, fruits and vegetables are rich sources of polyphenolic 
compounds like anthocyanins and flavonoids 19,20. The health promoting effects of the plant-based 
products could be due to interactions of the active phytochemical components with key cellular 
machinery involving inflammation, transcription and antioxidant systems 21-23. Most of these 
homeostatic cellular mechanisms are disrupted in aging and neurodegeneration 24,25. At the cellular 
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level, sirtuins, a family of Class III NAD+ dependent histone deacetylases, are implicated in 
several aging, metabolic and neurodegenerative pathways 26,27. Though most of its substrates are 
histones, they also act as upstream regulators for transcription factors such as FOXO and P53 28,29. 
Dietary polyphenols such as resveratrol and catechins are known to interact with sirtuins in 
modulating biochemical and signaling pathways 30,31. These natural compounds have 
demonstrated a therapeutic role in various neurodegenerative disorders and improving age-related 
cognitive decline 17,32. Blueberries in particular have been shown to improve or reverse age related 
deficits in both animal and clinical studies 33-39. The wild Alaskan bog blueberry (Vaccinum 
uliginosum) is a popular subsistence species endemic to the Arctic region. These Alaskan berries 
contain elevated levels of polyphenolic compounds (phenolic, anthocyanin and flavonoids) 
compared to commercially grown and temperate counterparts 40,41. We have previously established 
the beneficial effects of these endemic berries in improving markers of aging and neuronal health 
in both in-vitro and in-vivo model systems 42,43. However, there has been no study to address the 
mechanistic role of berry phytochemicals in eliminating toxic misfolded proteins, a key 
pathological marker and endpoint for drug targets.
Caenorhabditis elegans (C. elegans) is a very popular genetic model organism due to its 
ease of use, well defined aging properties, easy visualization and robust genetic malleability 44,45. 
Over the last decade, this model has also been explicitly used in studying age- and brain-related 
disorders, particularly protein misfolding diseases 46,47. In C. elegans, sir-2.1 (ortholog of 
mammalian Sirtuin 1) is a conserved regulator of aging mechanisms 48. We selected an α-synuclein 
expression/aggregation strain of C. elegans, OW13, which allows easy investigation and 
quantification of protein inclusions in vivo 49. We hypothesized that when treated with Alaskan 
bog blueberry extracts and polyphenolic fractions, the animals will have reduced protein 
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expression concomitant with improved behavioral motility and lifespan. We also hypothesized that 
this attenuation of protein expression is due to the interaction of polyphenols with sir-2.1.
2.3 Materials and Methods
2.3.1 Strains, Maintenance and Synchronization
C. elegans wild-type Bristol N2 and OW13 [unc54P ::α-synuclein ::YFP + unc-119(+)] strains 
used for the study were acquired from the Caenorhabditis Genetics Center (University of 
Minnesota). OW13 animals expresses human α-synuclein in its body wall muscle. The YFP tag is 
attached to the C-terminal of α-synuclein. The animals were cultured on nematode growth medium 
(NGM) plates using standard procedures 50 and maintained at 22 °C. The plates were seeded with 
Escherichia coli strain OP-50-1 or HT115 as appropriate for the experiment. The synchronous 
population was created using the standard egg-lay method (allowing 20-30 animals to lay eggs for 
4-6 hrs and then removing the adults at 22 °C) or by hypochlorite treatment (2 % sodium 
hypochlorite and 0.5 M NaOH) 51. All experimental plates (except those used for fecundity 
assessment) contained 0.04 μg/ml Fluorodeoxyuridine (FUdR) (Sigma) for progeny control.
2.3.2 Berry Extract Preparation
Wild specimens of Alaskan bog blueberries (Vaccinum uliginosum) were collected from 
interior Alaska. Crude extracts were prepared using 80% aqueous acetone and a rotary evaporator 
42. The specific polyphenolic fractions of anthocyanins and proanthocyanidins from the berries 
were extracted in the laboratory of Dr. Mary Ann Lila at Plants for Human Health Institute, North 
Carolina and kindly shared by Dr. Thomas Kuhn from the University of Alaska Fairbanks. All 
extracts were aliquoted and stored at -80 °C until further use. Instead of an extracted fraction of 
chlorogenic acid from blueberries, a pure form (Sigma) was used for the study to avoid 
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contamination with minor flavonols obtained during the fractionation process 38. All the specific 
fractions were reconstituted in deionized water with 0.1% DMSO to achieve a concentration of 
400 μg/ml. A fixed volume of deionized water with 0.1% DMSO was used as control. Total 
phenolic content and total anthocyanin content was measured as per the methods described in 42 
(Supplemental Table 2.1).
2.3.3 Treatment Administration
To administer the Alaskan berry treatments (both crude and fractions), a fixed volume of 
desired concentration was prepared in deionized water (with 0.1% DMSO for fractions) and spread 
on top of NGM plates seeded with live OP50-1/ HT115 E. coli bacteria. The control plates were 
spread only with a fixed volume of deionized water (with 0.1% DMSO for fraction study). The 
bacteria were cultured in Miller Luria-Bertani (LB) broth containing 50 pg/ml streptomycin or 
carbenicillin as appropriate for the experiment. The experimental population was transferred 
manually with a platinum pick at late larval L4 stage allowing the animals to ingest the extract. 
Subsequently, the animals were transferred every other day to a fresh plate with the same 
constituents until the experiments were performed. OW13 animals were treated with 0, 100, 200, 
or 400 pg/ml of crude berry extract or 0 and 400 pg/ml of the polyphenolic fractions. A single 
dose of 400 pg/ml of polyphenolic fractions was selected predominantly because the dose­
dependent study produced consistent attenuating effects at 400 pg/ml. Treatment started at larval 
stage L3 ( for lipid staining) and L4 stage (for all other experiments) and continued through days 
5, 7, and 12 when animals were tested.
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2.3.4 Lifespan Analysis
Following egg lay, synchronous population of 22 L4 animals were transferred into two 
replicates of each treatment (total of 44 animals). Survival was determined daily by visual 
observation or gentle prodding with a platinum wire under a dissecting microscope. 'Bagged' 
animals and those that crawled off the plates were censored and removed from the experiment 
(refer to Supplemental Table 2.3). Out of 44 animals, 8-12 animals were censored from each 
experiment. Each experiment was repeated at least three times.
2.3.5 Motility
The motility of aging animals at time point days 5 and 12 were measured based on a class based 
(A-B-C) system 52. The animals moving in a normal sinusoidal pattern were classified as A, the 
ones which required gentle prodding with a platinum wire were classified as B and those which 
did not respond or moved just head or tail in response to touch were classified as C.
2.3.6 Fecundity
Fecundity or viable progeny count was performed by plating age-matched adults on fresh 
treatment plates until the end of their reproductive phase or death. The eggs laid by the adults were 
allowed to hatch and develop at 22 °C for 48 h. The number of progeny produced by each 
individual every day was manually counted under a dissecting microscope.
2.3.7 RNA Interference
RNAi plates were prepared using IPTG and 4X concentrated HT115 bacteria for each gene 
target (L4440, sir-2.1 and daf-16) and covered with foil to protect from light. For each replicate of 
the experiment, control experiments were performed to compare the knockdown of the 
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fluorescence between GFP treatment to empty vector (L4440) (Supplemental Fig. 2.1). All the 
bacterial clones were sequenced (Supplemental Table 2.2).
2.3.8 Lipid Staining
Lipid staining was performed using Nile red dye (Sigma). The stock solution was prepared by 
dissolving 0.5 mg of the dye in 1 ml of acetone, and then mixed with E. coli OP50-1 53. L3 larvae 
of OW13 animals were added to the treatment plates containing 0.04 μg/ml of FuDR and blueberry 
extracts (0 and 400 μg/ml) and the imaging was performed at day 7 to monitor the lipid content.
2.3.9 DCF-DA Assay
Reactive oxygen species (ROS) were quantified using H2DCF-DA 42. In a 96-well plate, 50 
Ll of live age-synchronous, day 7 animals in M9 buffer were added to each well. Just before 
loading the plate into the microplate reader, 50 Ll of 100 mM 2,7-Dichlorofluorescin diacetate 
(DCF-DA, Sigma) in M9 was added to the wells. Basal and final fluorescence (after 1 h) was 
recorded at excitation of 485 nm and emission of 520 nm in a Biotek SynergyTM HT Multi-Mode 
Microplate Reader. Results were also normalized to total protein concentration using the BCA 
protein assay (Pierce Biotechnology). Each experiment was repeated three times.
2.3.10 qPCR Analysis
Total RNA was isolated from ~1000 day-7 adult animals using TRI Reagent (Life 
Technologies). Quantitative PCR (qPCR) experiments were performed with TaQMan gene 
expression analysis (Life Technologies) according to the protocol provided by the manufacturer 
to analyze the amount of mRNA of sir-2.1 and target genes: daf-16 and cep-1. qPCR data were 
analyzed as per Applied Biosystem's software protocol using cdc-42 and pmp-3 genes as an 
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internal reference for normalization. The primer set (Life Technologies, Grand Island, NY) used 
for the experiments were: sir-2.1 (Ce02459015_g1), daf-16 (Ce02422838_m1), cep-1 
(Ce02410616_g1), cdc-42 (Ce02435136_g1 4) and pmp-3 (Ce02485188_m1).
2.3.11 Protein Extraction and Quantification
Day 7 animals were washed 3 times with distilled water, settled with gravity and then 
homogenized with a sonicator for 30-60s in 100-200 μL of a lysis buffer (50 mM Tris-HCl 
pH7.5, 150 mM NaCl, 1 mM EDTA, 0.2 mM DTT, 1% Triton X-100, v/v; 10% glycerol, v/v) 
with a proteinase inhibitor (1 mM PMSF). The lysate was centrifuged at 11,000* g at 4 °C for 
10 min. The supernatant was collected, and protein samples were stored at -80 °C. Protein 
concentration was determined with the BCA assay kit (Pierce Biotechnology).
2.3.12 Western Blots
For western blots, 60 μg of total protein was mixed with 4X Laemmli loading buffer (VWR 
Life Sciences), heated at 100 °C for 10 min, then loaded in 12% Tris-Glycine gels (Invitrogen) 
consisting of a top 4% stacking gel and a bottom 12% resolving gel, and resolved by 
electrophoresis at 190 V in a running buffer (25 mM Tris base, 190 mM glycine, and 0.1% SDS 
(w/v)). Proteins were transferred to a Nitrocellulose membrane (Thermo scientific catalogue 
88024) at 75 V for 3 hours and was blocked at 4 °C with 5% Bovine Serum Albumin (BSA) for 
2.5 hours. The membrane was incubated in primary antibody (1:1000 dilution, rabbit anti-GFP, 
Invitrogen Life Technologies) overnight at 4 °C. The membrane was then washed three times 
with 1* Tris buffered saline with Tween 20 (TBS-T; 0.05 M Tris-HCl, 0.15 M NaCl, 0.1% (v/v) 
Tween 20, pH 7.5) + 1% BSA and incubated with a secondary antibody solution (1:10,000 
dilution, Horse radish peroxidase conjugated goat anti-rabbit; Invitrogen) for 2.5 hours. After 
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three washes with 1* TBS-T, the membrane was developed with SuperSignal™ West Pico 
PLUS Chemiluminescent Substrate (Thermofisher scientific) and imaged using a ChemiDoc- 
It2 imager at constant exposure settings. For probing with Actin as the loading control, the same 
membrane was incubated in a stripping buffer (0.1% SDS, w/v; 1% Tween 20, v/v; 200 mM 
glycine, pH 2.2) for 2 x 10 min, washed twice in PBS, then twice in 1* TBS-T + 1% BSA, prior 
to being blocked in 5 % BSA for 2.5 hours. The membrane was treated to the primary antibody 
(1:1000 dilution, rabbit anti-Actin, Abcam) and the secondary antibody (1: 10,000 dilution, 
Horse radish peroxidase conjugated goat anti-rabbit, Invitrogen) and developed similar to the 
anti-GFP detection. For each treatment, protein samples were pooled from three biological 
replicates. The experiment was repeated twice.
2.3.13 Microscopy and Image Quantification
All images were acquired with a Zeiss LSM 510 laser scanning confocal microscope at 
constant magnification and exposure settings. Images were analyzed with ImageJ (National 
Institute of Health). Both α-synuclein and lipid content were quantified based on measurement 
of total fluorescence. A box of fixed height and width was drawn in the head region of the 
animal. Relative fluorescent intensity was determined by measuring the average integrated 
density after subtracting the background. Western blot lanes were imaged using ImageJ by 
measuring the relative band intensity and normalized to endogenous control - actin.
2.3.14 Statistical Analysis
Statistical analysis was performed in SPSS (Version 22) for motility (ordinal logistic model) 
and lifespan (Kaplan-Meier log rank survival) experiments. All other statistical analysis was 
performed in Graph Pad Prism (GraphPad Software, Inc). Treatment effect between groups were
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tested using one-way or two-way analysis of variance (ANOVA) or t-test. Pairwise comparisons 
for significant differences between treatment groups were made using Tukey's t-tests.
2.4 Results
2.4.1 Crude extract of Alaskan bog blueberry Attenuated Expression of Human α-synuclein in C. 
elegans.
OW13 animals treated with different doses of crude berry extract (0, 100, 200, 400 μg/ml) 
were observed on day 7 of the adulthood for protein expression. Two doses of the extract (100 and 
400 pg/ml) significantly reduced protein accumulation (One-way ANOVA, p<0.005). The 
fluorescent intensity of the protein accumulation was reduced by about 25-38 % (Fig. 2.1) for the 
groups administered 100 pg/ml (Tukey's post hoc t-test, p<0.01) and 400 pg/ml (Tukey's post hoc 
t-test, p<0.001) doses. The 200 pg/ml dose was not significantly different from the control (0 
pg/ml) (One-way ANOVA, p>0.4). To further corroborate these findings, western blot analysis 
was conducted using antibodies probing the YFP part of the α-synuclein ::YFP chimeric protein, 
to measure the protein expression in whole worm extracts on the 7th day of adulthood. The protein 
expression was reduced by about 40% (Fig. 2.1) for the 400 pg/ml doses when compared to the 
control (t-test, p<0.02).
We also investigated whether these attenuating effects of blueberries were due to secondary 
responses in C. elegans resulting from interactions between the live food source, E. coli OP50-1, 
and the treatments. Transgenic C. elegans were grown on Alaskan blueberry treatment with heat- 
killed OP50-1 E. coli. In the presence of dead bacteria, blueberry treatment resulted in attenuated 
protein expression when compared to the untreated control (One-way ANOVA, p<0.02). A 
Tukey's post hoc t-test further indicated significant differences between control (0 pg/ml) and 
treatment groups (100 and 400 pg/ml) (p<0.01 and p<0.001, respectively; Supplemental Fig. 2.2).
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2.4.2 Alaskan Bog Blueberry Polyphenolic Fraction Reduced Expression of Human α-synuclein 
in C. elegans.
Based on our initial findings (Fig. 2.1), we further aimed to determine which specific fraction 
reduced the protein expression in C. elegans. Chlorogenic acid (CA) had no effect on protein 
expression (One-way ANOVA, p>0.6) (Fig. 2.2). However, treatment with both fractions rich in 
proanthocyanidins (PAC) and anthocyanin (ANT) reduced α-synuclein expression significantly 
compared to the control (One-way ANOVA, p<0.0001). The protein accumulation was reduced 
by about 39% for both PAC (Tukey's post hoc t-test, p <0.002) and ANT (Tukey's post hoc t-test, 
p <0.0002) groups (Fig. 2.2).
2.4.3 Alaskan Bog Blueberry Polyphenols Reduced Human α-synuclein Expression in C. elegans 
through RNA Interference Mediating sir-2.1.
No significant effect was observed for RNAi genetic treatment and blueberry treatment (Two­
way ANOVA, p>0.6 and p>0.7 respectively). However, there was a significant interaction effect 
between RNAi and blueberry treatment (Two-way ANOVA, p<0.0003). At day 7 of adulthood, 
silencing of sir-2.1 decreased protein expression by about 30% (Tukey's post hoc t-test, p<0.001) 
(Fig. 2.3) compared to the empty vector, L4440. Also, when treated with blueberry extract (400 
μg/ml), the animals fed with L4440 demonstrated reduced protein expression by 34% (Tukey's 
post hoc t-test, p<0.001) (Fig. 2.3) compared to the animals treated with null control of the extract 
(0 pg/ml). Most strikingly, when sir-2.1 was silenced in animals and treated with crude blueberry 
extract (400 μg/ml), the protein expression significantly increased by 29% compared to the control 
sir-2.1 group (Tukey's post hoc t-test, p<0.01) (Fig. 2.3). There was no significance observed 
within daf-16 groups (0 and 400 pg/ml) (Tukey's post hoc t-test, p>0.05) as well as between daf- 
16 and other treatment groups (Tukey's post hoc t-test, p>0.05).
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2.4.4 Alaskan Bog Blueberry Extract Improved Motility Mediated by sir-2.1 in C. elegans 
Expressing Human α-synuclein.
When treated with Alaskan blueberry crude extract (0, 100, 200 and 400 pg/ml), animals at day 
5 of adulthood had normal motility compared to the controls (Fig. 2.4A). However, at day 12 of 
adulthood, the animals treated with 100 and 400 pg/ml of crude extract of Alaskan blueberry 
maintained normal motility or had less decline in motility (more Class A and B compared to 
immobile Class C) compared to the other groups (Ordinal logistic model, p<0.01) (Fig. 2.4B).
When animals with a silenced sir-2.1 gene were treated with crude extract of Alaskan blueberry, 
the α-synuclein expression significantly increased. We wanted to further investigate whether 
silencing sir-2.1 gene had any effect on the animals treated with the Alaskan blueberry extract (0 
and 400 pg/ml). Animals in all the groups exhibited normal motility at day 5 (Fig. 2.5A). However, 
at day 12 of adulthood the control group treated with blueberries (L4440 + BB) had more A animals 
compared to the empty vector control (L4440) (ordinal logistic model, p<0.01) (Fig. 2.5B). 
Strikingly, at day 12 of adulthood the group with the sir-2.1 knockdown had lesser class C animals 
compared to empty vector, L4440. Finally, when sir-2.1 knockdown animals were treated with 
400 pg/ml of crude extract of Alaskan blueberry, the motility of the animals worsened significantly 
compared to all other groups (Ordinal logistic model, p<0.01).
2.4.5. Alaskan Bog Blueberry Treatments did not Affect Lifespan or Total Progeny in C. elegans 
Expressing Human α-synuclein.
There was no significant change in mean lifespan among OW13 strain groups treated 
with tested doses of blueberry extract (0, 100, 200 and 400 pg/ml) (Kaplan Meir statistics, p> 0.05) 
(Fig. 2.6A). Interestingly, when animals were treated with genetic treatments (empty vector 
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control: L4440 and sir-2.1) and 400 Lg/ml of blueberry extract, no significant effect was found in 
the mean lifespan among the groups (Kaplan Meir statistics, p> 0.05) (Fig. 2.6B).
No significant differences were observed for the total progeny produced between groups 
treated with Alaskan berry extract (0, 100, 200 and 400 Lg/ml) (One-Way ANOVA, p> 0.05) (Fig. 
7A). The RNAi treatment groups (L4440, sir -2.1) in combination with crude extract of blueberry 
(0 and 400 Lg/ml) also were not significantly different (Two-way ANOVA, RNAi treatment effect 
p>0.05; blueberry treatment effect p>0.05; interaction effect p>0.05) (Fig. 2.7B).
2.4.6 Alaskan Bog Blueberry Restored Lipid Content in C. elegans Expressing Human a- 
synuclein.
At day 7 of adulthood, the fat levels of N2 were found to be significantly higher than the 
OW13 strain, which over expressed α-synuclein in its body (One-way ANOVA, p<0.001) (Fig. 
2.8A and 2.8B). However, treatment with blueberry extract (400 Lg/ml) significantly increased 
total fat content compared to the untreated OW13 group (Tukey's post hoc t-test, p<0.001) (Fig. 
2.8A and 2.8B). At day 7 of adulthood, treatment with 400 Lg/ml of blueberry extract, showed a 
trend towards elevated levels of ROS (t-test, p=0.07) (Fig. 2.8C) compared to control.
2.4.7 Alaskan Bog Blueberry Treatment Reduced Gene Expression Levels of sir-2.1 in C. elegans 
Expressing Human α-synuclein
A significant difference was observed for gene, blueberry treatment and its interaction 
(Two-way ANOVA, p<0.03, p<0.02 and p<0.002, respectively). At day 7 of adulthood, the gene 
expression level of sir-2.1 was significantly higher than its downstream targets: daf-16 and cep-1 
in untreated control groups (Tukey's post hoc t-test, p< 0.01). When compared to 400 Lg/ml 
blueberry treated group, the relative expression of sir-2.1 was significantly decreased by almost 
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50% (Tukey's post hoc t- test, p<0.001) (Fig. 2.9). However, there were no significant differences 
(Tukey's post hoc test, p>0.5) (Fig. 2.9) between the gene expression levels of daf-16 and cep-1 in 
animals of both treatment (400 Lg/ml) and control (0 Lg/ml) groups.
2.6 Conclusion
In summary, our results identify a sir-2.1-mediated mechanism through which Alaskan 
blueberry polyphenols reduce α-synuclein expression in C. elegans, while also increasing lipid 
content and motility. These results indicate that, Sirtuin 1 can act as a double-edge sword in cellular 
overload conditions due to protein aggregation and partial down regulation of Sirtuin 1 that can 
restore homeostatic balance. Through the current study, we have also shown how xenohormetic 
properties of blueberries can trigger the beneficial effect of endogenous ROS signaling molecules. 
Overall, this study supports the future exploration of photochemical-induced alternative pathways 
for cell survival in various neurodegenerative disorders.
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2.5 Discussion
Studies have shown that the effect of natural 'indigenous diets' have several health benefits 
over modern western diets 54,55. However, a comprehensive evaluation of the role of photochemical 
components in influencing cellular mechanisms is sparsely explored in relationship to aging and 
neurodegeneration. The current study resulted in several novel findings. We report for the first 
time that crude extract of Alaskan bog blueberry attenuated human α-synuclein aggregation and 
improved overall motility as expressed in a transgenic aged C. elegans model that expressed a- 
synuclein (OW13). Interestingly, we did not find a dose-dependent effect. Instead, we observed a 
bimodal or biphasic response in both aggregate reduction and motility enhancement. This pattern 
of response has also been reported earlier with other phytochemicals in both in-vivo and in-vitro 
models 42,56,57. The current results are of translational significance since α-synuclein aggregation 
is a typical pathological feature of protein misfolding diseases such as Parkinson's disease 4. A 
study in a yeast model suggests the therapeutic role of polyphenols like flavonoids in reducing a- 
synuclein toxicity 58. Other studies have also revealed the role of flavanoid sub-classes like 
anthocyanin and proanthocyanidin in conferring protection against oxidative stress in-vitro and 
extending lifespan in C. elegans 38,59,60. In this current study, anthocyanin and proanthocyanidin 
fraction of Alaskan blueberry reduced protein over expression in a transgenic strain of C. elegans. 
Our results are possibly due to Alaskan blueberries growing under more extreme environmental 
conditions, such as extreme Arctic temperatures and 24-hours sunlight exposure (UV exposure) 
during summer months, and thereby having different anthocyanin content 61. In addition, doses of 
Alaskan blueberry extract did not influence lifespan and total fecundity in the nematode strain. 
Studies have shown that improved lifespan can be uncoupled from increased healthspan 62. In our 
study, blueberry bimodally improved one measure of healthspan (motility) with no overall effect 
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on the other (fecundity). Importantly, blueberry treatment did not exhibit a uniformly toxic effect 
because it did not reduce lifespan and did not decrease fertility in this transgenic model of C. 
elegans.
In the past decade, sirtuins have received extensive scrutiny in relation to various age- 
related molecular mechanisms and have been studied across various model systems 63,64. 
Particularly, mammalian Sirtuin 1, due to its high abundance in the brain, has drawn much interest 
in the field of neuroscience including synaptic plasticity and cognition 65,66. At the same time, 
research that elucidates the role of natural polyphenols in activating Sirtuin 1 and affecting 
pathologies of protein misfolding diseases has increased 67-69. Results from these studies indicate 
that triggering Sirtuin 1 enhances its deacetylase activity further inducing different pro-survival 
pathways 70-72. While the beneficial effect of Sirtuin 1 activation has been comprehensively 
demonstrated, there are also studies that illuminate the role of Sirtuin 1 inhibition in 
neuroprotection and improving cellular functions in diseased conditions 73-78. Genetic and 
pharmacological studies have found that reduced Sirtuin 1 activity can be beneficial in improving 
neurodegenerative pathologies in Drosophila melanogaster, mammalian cells and mouse models 
of Huntington's and Alzheimer's disease 75,79-82. In alignment with these studies, we are reporting 
for the first time the protective effects of Alaskan blueberry through reduction of sir-2.1 gene 
expression in a model of C. elegans displaying Parkinson-like molecular pathology. We found that 
genetically silencing (not deleting) sir-2.1 greatly reduced the α-synuclein expression in OW13. 
This is further corroborated by the gene expression results suggesting higher gene expression 
levels of sir-2.1 in the control group compared to the blueberry treated group and other downstream 
targets in OW13. Higher activity of Sirtuin 1 in metabolically compromised conditions has been 
linked to higher energy expenditure, which may potentially diminish the effect of the downstream 
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substrates 76,77,83. In our experimental model of protein overload, lower gene expression levels of 
downstream substrates such as daf-16 and cep-1 compared to sir-2.1 in untreated controls probably 
could be justified due to the same mechanism. Strikingly, the basal level of sir-2.1 was also 
elevated in OW13 when compared to healthy wild-type N2 (Supplemental Fig. 3). The profitable 
role of Sirtuin 1 activation can depend on physiological state of cells and actually can be 
detrimental when cells are in stress76,77. In our experiments, we observed elevated gene expression 
levels of sir-2.1 in a model subjected to proteotoxic stress in the form of α-synuclein aggregation.
Research showed how studying alterations in downstream sirtuin substrates, like FOXO, 
P53 and PGC-1a, can be used as a treatment strategy in protein aggregating diseases 27. Based on 
this, we investigated the effects of blueberry extract on two molecular targets of sir-2.1: daf-16 
(C. elegans ortholog for mammalian FOXO) and cep-1 (C. elegans ortholog for mammalian p53). 
of sir-2.1 gene in blueberry-treated animals showed an increase in α-synuclein expression. Results 
also demonstrated very low mRNA levels of sir-2.1 in blueberry-treated group compared to 
controls. However, we also observed that genetic silencing of daf-16 in both control and treatment 
groups had no effect on the protein expression. Overall, this may indicate that reduced gene 
expression of sir-2.1 (not complete deletion) could be a potential mechanism through which 
blueberry exerts its beneficial effect in reducing α-synuclein expression and such pathways may 
not involve changes in downstream protein targets. Reduction in Sirtuin 1 gene expression through 
genetic or pharmacological manipulation has been shown to improve cellular symptoms and 
disease-specific phenotypes in models expressing mutant huntingtin protein 82. Smith et al. (2014) 
showed that reducing levels of Sirtuin 1 can result in increased activity of other histone-acetylating 
enzymes, which can ameliorate the pathology82. On the other hand, increased expression of Sirtuin 
1 may deacetylate and repress functions of the CREB-binding protein (CBP)84 further reducing 
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cell activity. Impaired CREB signaling and reduced transcription also have been reported in cells 
that overexpress α-synuclein 85. However, no direct correlations have been drawn on how reduced 
activity of Sirtuin 1 using pharmacological interventions can possibly improve pathology of 
synucleinopathies through modulating transcription factors such as CREB. Though we do not 
speculate on the exact molecular interaction or cross talks, this study strongly advocates for future 
investigations of such novel mechanisms.
Protein misfolding diseases like Parkinson's are often associated with alterations in total 
lipid content 53,86,87. Increased lipid content has been used as a surrogate measure of improved 
cellular pathology in studies evaluating natural compounds as potential therapeutics to treat 
Parkinson's disease 53,88-90. However, these studies have not highlighted the exact mechanism 
behind the effect. We found higher fat levels in the wild-type N2 positive control compared to 
OW13 strain. The lower fat content in OW13 strain was possibly due to the metabolic burden of 
protein aggregation. The lipid levels were restored in OW13 animals treated with 400 Lg/ml of 
blueberry extract. This pattern of results is consistent with those shown by others 53,88-90. However, 
much to our surprise the fat content and ROS measures did not correlate with each other as 
anticipated. We found that the blueberry extracts marginally increased the ROS levels, a 
phenomenon previously reported with Alaskan bog blueberries 42. Xenohormesis is a phenomenon 
that explains how environmentally stressed plants produce bioactive compounds that confer stress 
resistance and survival benefits to animals that consume them 91. Plants, such as blueberries, when 
subjected to harsh environmental stressors produce secondary metabolites such as polyphenols 41. 
Consumption of these plant metabolites by animals can activate stress response pathways other 
than regular antioxidant effects, thereby improving overall aging and health 92,93. Additionally, 
Alaskan blueberries have been shown to inhibit inflammation in neuronal cell cultures through 
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differential biological mechanisms other than their popular image of antioxidant ROS scavengers 
43
Several studies demonstrate that low levels of ROS can be beneficial in activating signaling 
pathways to initiate biological processes 94,95. In C. elegans, ROS in low concentrations can act as 
a secondary messenger molecule leading to fat accumulation 96. This increase in fat content has 
been found to have contrasting effects on longevity 96 possibly due to differences in structure of 
the fat, its localization, or the time point of its accumulation. At day 7 of adulthood, we observed 
that lipid content was restored in parallel with reduction in α-synuclein expression. Important 
questions arise from this: What is the mechanistic approach resulting in such 'beneficial' increase 
in lipid levels, and; are such pathways evolutionarily conserved? Future studies aiming at further 
characterization of the increased fat content could be useful in answering such questions. Finally, 
inhibition of Sirtuin 1 has also been found to increase production of ROS due to its positive 
regulation of antioxidant enzymes 97. In the current context of investigation, we believe a marginal 
increase of ROS due to sir-2.1 inhibition by blueberries might activate crucial cell survival 
pathways overcoming the protein overload. However, such complex interactions between 
proteostatis, sirtuins, ROS and lipid content should be subjected to further investigation in a variety 
of cellular and animal models.
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2.8 Figures and Tables
Figure 2.1 Crude extract of Alaskan Blueberry Reduced Expression of α-synuclein in the OW13 
Strain of C. elegans
(A) Graphical representation of fluorescence intensity of the OW13 day 7 animals fed on different 
concentrations of Alaskan blueberry crude extract (0, 100, 200 and 400 Lg/ml) from Larval L4 
stage. The data represent the mean ± SEM (n = 20-25 animals per group) with significant 
differences between the control and extract treatments (0 and 100 Lg/ml, 0 and 400 Lg/ml) 
*p<0.01, *** p<0.001. Dose 200 Lg/ml was not significantly different from control (p>0.4). Each 
experiment was repeated three times. (B) Representative confocal images of the α-synuclein/YFP 
expression in the head region of day 7 OW13 animals, magnification 40X and scale bar 50 Lm.
(C) Original western blot images of α-synuclein protein of the OW13 day 7 animals fed on 
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concentrations of Alaskan blueberry crude extract (0 and 400 μg/ml). Blots of actin were used as 
a protein loading control. (D) Graphical representation of quantification of α-synuclein protein 
bands from Western blots. The intensity of α-synuclein protein was normalized to actin and 
presented as a percentage. Each experiment was repeated twice. For each treatment of each 
experiment, protein samples were pooled from three biological replicates. The data represent the 
mean ± SEM with significant differences between control and extract treatments (0 and 400 μg/ml, 
* p < 0.02).
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Figure 2.2 Alaskan Blueberry Polyphenols Reduced Expression of α-synuclein in the OW13 Strain 
of C. elegans
(A) Graphical representation of fluorescence intensity of the OW13 day 7 animals fed on different 
polyphenols found in Alaskan blueberry: CA=Chlorogenic acid, PAC= Proanthocyanidins, ANT= 
Anthocyanins from Larval L4 stage. A concentration of 400 μg/ml was used for all extracts and 
0.1% DMSO in deionized water was used as a control. The data represent the mean ± SEM (n = 
20-25 animals per group) with significant differences between the control and treatments, 
**p<0.001, ***p<0.0001. Each experiment was repeated three times. (B) Representative confocal 
images of the α-synuclein/YFP expression in the head region of day 7 OW13 animals, 
magnification 40X and scale bar 50 pm.
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Figure 2.3 Alaskan Blueberry Polyphenols Reduced Expression of α-synuclein in the OW13 strain 
of C. elegans Through a Sirtuin Mediated Pathway.
(A) Graphical representation of fluorescence intensity of the day 7 OW13 animals fed on different 
genetic RNA interference treatments (L4440, sir-2.1 and daf-16) and Alaskan blueberry (0 and 
400 μg/ml) from larval L4 stage. Empty vector L4440 was considered as a control. The data 
represent the mean ± SEM (n = 20-25 animals per group) with significant differences between the 
control and treatments at **p<0.001 and ***p<0.0001. Each experiment was repeated three times.
(B) Representative confocal images of the α-synuclein/YFP expression in the head region of day 
7 OW13 animals, magnification 40X and scale bar 50 □m.
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Figure 2.4 Alaskan Bog Blueberry Polyphenols Improved Motility in Aged (Day 12) OW13 Strain 
of C. elegans.
Percent per motility class of middle age (day 5 adults; A) and old age (day 12 adults; B) animals 
treated with different concentrations of Alaskan bog blueberry extract (0, 100, 200 and 400 μg/ml) 
from larval L4 stage. Class A animals (dark gray) moved normally and spontaneously, class B 
animals (light gray) moved abnormally and may have required prodding, and class C animals 
(black) were unable to move or moved just head or tail in response to touch (n = 20 animals per 
group). Each experiment was repeated at least three times.
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Figure 2.5 Reduction of sir-2.1 Expression Reverses the Motility Improving Effects of Alaskan 
Bog Blueberry Polyphenols in Aged (Day 12) OW13 Strain of C. elegans.
Percent per motility class of middle age (day 5 adults; A) and old age (day 12 adults; B) animals 
treated with different genetic RNA interference treatments (L4440, sir-2.1 and daf-16) and 
Alaskan bog blueberry extract (0 and 400 μg/ml) from larval L4 stage. Empty vector L4440 was 
used as control. Class A animals (dark gray) moved normally and spontaneously, class B animals 
(light gray) moved abnormally and may have required prodding, and class C animals (black) were 
unable to move or moved just head or tail in response to touch (n = 20 animals per group). Each 
experiment was repeated at least three times.
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Figure 2.6 Alaskan Bog Blueberry did not Alter Lifespan in OW13 Strain of C. elegans.
(A) Representative survival curves for animals treated with crude extract of blueberries (0, 100,
200 and 400 pg/ml) from larval L4 stage. There was no significant difference in lifespan extension 
(p > 0.05; Kaplan-Meier log-rank test) among the groups. Each experiment was repeated at least 
three times (n = 44 animals per treatment). (B) Representative survival curves for animals treated 
with RNA interference treatments (L4440 and sir-2.1) and crude extract of blueberries/BB (0 and
400 pg/ml) from larval L4 stage. There was no significant difference in lifespan extension (p > 
0.05; Kaplan-Meier log-rank test) among the groups. Each experiment was repeated at least three 
times (n = 44 animals per treatment).
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Figure 2.7 Alaskan Bog Blueberry and/or RNA Interference Treatments did not Influence Total 
Fecundity in OW13 Strain of C. elegans.
(A) Graphical representation of total fecundity of the OW13 animals fed on different 
concentrations of Alaskan bog blueberry crude extract (0, 100, 200 and 400 μg/ml) from larval L4 
stage. The data represent the mean ± SEM (n = 10 animals per group) with no significant 
differences among the control and treatments, p>0.05. Each experiment was repeated three times.
(B) Graphical representation of total fecundity of the OW13 animals fed on different genetic RNA 
interference treatments (L4440 and sir-2.1) and concentrations of Alaskan blueberry crude extract 
(0 and 400 μg/ml). The data represent the mean ± SEM (n =10 animals per group) with no 
significant differences between the control and treatments, p>0.05. Each experiment was repeated 
three times.
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Figure 2.8 Alaskan Bog Blueberry Increased Lipid Content by a Marginal Increase in Reactive 
Oxygen Species in OW13 Strain of C. elegans.
(A) Graphical representation for fluorescence intensity for Nile red staining of day 7 wild-type N2 
(control) and OW13 animals fed Alaskan bog blueberry extract (0 and 400 μg/ml) from larval L3 
stage. The data represent the mean ± SEM (n = 20-25 animals per group) with significant 
differences between the control and treatments at ***p<0.001. Each experiment was repeated at 
least three times. (B) Representative confocal images of the intestine of day 7 wild-type N2 
(control) and OW13 animals fed Alaskan bog blueberry extract (0 and 400 □g/ml), magnification 
20X and scale bar 50 Dm. (C) The change in endogenous ROS was measured by DCF-DA assay 
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at day 7 of adulthood after treatment with crude extract of blueberries (0 and 400 pg/ml). Bars 
represent mean ± SEM of each replicate, with three technical replicates for the DCF-DA assay. 
#p= 0.07.
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Figure 2.9 Alaskan Bog Blueberry Extract Reduced the Gene Expression of sir-2.1 in OW13 Strain 
of C. elegans.
qPCR analysis of mRNA levels of sir-2.1, daf-16 and cep-1 (400 μg/ml of crude blueberry or BB 
extract) in day 7 OW13 animals. qPCR reactions were run in triplicates for each gene. Each 
experiment was repeated at least three times. The data represent the mean ± SEM at **p<0.01 and 
***P<0.001.
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Supplemental Figure 2.1 Graphical Representation of Fluorescence Intensity of the OW13 
Animals Fed on Different RNA Interference Treatments: L4440 and GFP. The data represent the 
mean ± SEM (n = 15-20 animals per group) with a significant difference between the control and 
GFP treatment, p<0.01. This was used as a validation plate control for RNA interference 
experiments.
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Supplemental Figure 2.2 Graphical Representation of Fluorescence Intensity of the OW13 animals 
Fed on Different Concentrations of Alaskan Bog Blueberry Crude Extract (0, 100, 200 and 400 
pg/ml) and heat-killed OP-50-1 as a food source. The data represent the mean ± SEM (n = 15-16 
animals per group) with significant differences between the control and treatments at *p<0.01 and 
**p<0.001. Each experiment was repeated two times.
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Supplemental Figure 2.3 qPCR Analysis of mRNA Levels of sir-2.1 Between Wild-type N2 and
α-synuclein Overexpressing OW13 strain. qPCR reactions were run in triplicates for each strain.
Each experiment was repeated at least two times. The data represent the mean ± SEM; *p<0.05.
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Supplemental Table 2.1 Total Phenolic Content (Quantified by Folin-Ciocalteu assay with Gallic
Acid Equivalent), and Anthocyanin Content (Quantified by pH-differential with Cyanidin-3- 
glucoside) of Alaskan Bog Blueberry.
Value*
Total Phenolic content (mg GAE g-1 FW) 198.2±1.4
Total anthocyanin (mg C3G L-1 FW) 285.7±8.2
*Data is represented as mean ± SEM for each replicate. Each assay was run in triplicate. The assays 
were performed following the methods of Scerbak et al., 2016. The values were used for the 
biochemical quantification of the berry extracts to compare the content reported in Scerbak et al. 
(2016). The values reported are similar to that reported in previous study.
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Supplemental Table 2.2 Sequencing Results of the RNA Interference Clones.
Name of Clones Sequences
L4440 GGGGNCANNNNCNATACGGGNCGANTGGNTG
ACCGGNCCCCCCCCNAAGG
CNNGGGNTNANTAACNTTGATATCCCCCTTTA
AAAAGAATGAGCAGNTTT
TGATGCCAAAAGCTCGATANATCCCGGGAAAT
AACGCTTCTTACATCGAT
GAACGAAATCNNNNACCAAAAATTTCAANNCT
CCAAGCGAACGCGCTCAA
CACAACTCANAAACATCTAAAGCGGAATTNNN
TTATNANNACAATTCNTC
ATAACCTTCGCAATGTCTCACCNNNNAANCAT
CNCACACNTAGTTCCAAA
CTTNNCCATCNNATCANCATTCATTCCCACAAA
NCAGACTTCGANGACCA
CAAATCCGNNNNAAAANNNNTTACGTGGANN
GCTGGNCCGANNGGNNNNN
73
ANNNNGNATATTCTANNGNNTNATATTCCNNN
NTNNCAACAATACNNACT
NNNAGATNNTTNATTNNCCNNGAGCCTCNNNC
ANNNGNNGANNAACNATC
CANNNTTCATAAAA
sir-2.1 NNNNNNNNNNNNNNNGGCNNNNNNNNNNNNG
GGNNNNNNNNNNNNGNNNN
NNGNNNNNANNNGCNNNNNNNGNNCNGCANC
NNNNNNNNNNNNANNNNNN
NNNNNNNNNNNNNNANAGNANNNNANGNNN
NNNNNNNNAANNNNNNNNNA
ANNNNNTCNGNNNNNACAAAGTCANNTAGCG
NNNNNNNNNTNNNNNNNNN
NNNNGNNNNNGNNNNGGCNNNNGNNGNNNNA
TANNNNNNACACNAGCNNN
CNCANNNNNNCTCGTGATGAANNNNNCGAGCT
ANTNNCNACGTTTCTAGA
NNNAATGAGCANNCNNTCCCAGGAANGNNNN
TTTGANGANNNNNNNNCTG
74
AACAAAAAATNATTANTTGTAAGGCNGNNNNG
TAGGTTGTTTAGAAATAT
TTTCTAACTTTTGACTTTTTAATTTCCAAAACTA
CTCACCGCAACACACT
TATTGTCATGGAGCATCTCAGTAATGCTCAGCA
GCCTTGGATGCTTTATT
TTCTTTAGGATAGCGTCCGAATTCCGTGCATCA
TCGTCATCTTCTGACTT
ATGCTTTTGTATTTCCTGGAAATCATTCTTCTC
GGAATCCATCAAATCGT
CAACGACCGACATTCTCGGTTTCTTCAATGTTG
GCTCATCACTCGAATCA
TCATTACTCTTCTCTTTCATACATATATTCAAA
AAGTTTTCCTGTGAAAT
AAGCTGTCGTTTGTTTTGTGAAGGCTTTTGTGA
TTTCGATTTTCCTTGTT
GTTCCATAATTGAATCATAAGATGTAATCAGTT
CAGTGAAGGAGCCTCCN
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AGACTGAAACAGATATCTCTGATGGTGCCATC
ACAATTTCCGAGCAATTC
NATATCCGCATTATNATGTTGGAGGGANTCTCT
GTTGANTAGAATTCGTG
GACCATTCTTATCNACACNATGAGGAATTNAT
GCNACTGGTGGAACTTCT
ANAGAANATCCNATCACTACNTAANATCTACT
TNNTGCTTNNCTTCTGTA
NCATGNTGATGAANTNNCNTNCNANANCNNNC
NAAGATANANATTNNNTT
GATGACNNNNNANNNTTNCATGNNANNCNCN
NNTCANACTNNNCNCNANN
NNNTNCNNNANTNNNATNTNNCNNNNNCNNN
NNNGNNNCNNNTNNNTNNA
NANNNGNNNNTNCNNNNNNNNNNANNNCNNN
NNNNNNNNNNNNNNNNNNA
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNAAN
NNNNNNNNNNNNNNNNNNNNNN
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daf-16 NNNNNNNNNNNNNNNNGNNCNNNNNNNNNNN
NGGNCCNNCCTCGAGGTCG
ACGGTATCGATAAGCTTGATATCACAAGTTTGT
ACAAAAAAGCAGGCTTG
ATGGAGATGCTGGTAGATCAGGGAACTGATGC
ATCGTCATCCGCCTCCAC
GTCCACCTCATCTGTTTCGAGATTCGGAGCGGA
CACGTTCATGAATACAC
CGGATGATGTGATGATGAATGATGATATGGAA
CCGATTCCTCGTGATCGG
TGCAATACGTGGCCAATGCGTAGGCCGCAACT
CGAACCACCACTCAACTC
GAGTCCCATTATTCATGAACAAATTCCTGAAG
AAGATGCTGACCTATACG
GGAGCAATGAGCAATGTGGACAGCTCGGCGGA
GCATCTTCAAACGGGTCG
ACAGCAATGCTTCATACTCCAGATGGAAGCAA
TTCTCATCAGACATCGTT
77
TCCTTCGGAAATGTCCGAATCGCCAGACGATA
CCGTATCGGGAAAAAAGA
CAACGACCAGACGGAACGCTTGGGGAAATATG
TCATATGCTGAACTTATC
ACTACAGCCATTATGGCTAGTCCAGAGAAACG
GTTAACTCTTGCACAAGT
TTACGAATGGATGGTCCAGAATGTTCCATACTT
CAGGGATAAGGGAGATT
CGAACAGTTCAGCTGGATGGAAGAACTCGATC
CGTCACAATCTGTCTCTT
CATTCTCGTTTCATGCGAATTCAGAATGAAGG
AGCCGGAAAGAGCTCGTG
GTGGGTTATTAATCCAGATGCAAAGCCAGGAA
GGAATCCACGGCGTACAC
GTGAACGATCCAATACTATTGAGACGACTACA
AAGGCTCAACTCGAAAAA
TCTCGCCGCGGAGCCAAGAAGAGGATAAAGG
AGAGAGCATTGATGGGCTC
78
CCTTCACTCGACACTTAATGGAAATTCGATTGC
CGGATCGATTCAAACGA
TTTCTCACGATTTGTATGATGATGATTCAATGC
AAGGAGCATTTGATAAC
GTTCCATCATCTTTCCGTCCCCGAACTCAATCG
AACCTCTCGATTCCTGG
ATCGTCGTCTCGTGTTTCTCCAGCTATTGGAAG
TGATATCTATGATGATC
TAGAATTCCCATCATGGGTTGGNCGAATCCGG
TTCCAGCAATTTCCAAGT
GANNTTGGTTGATAAGAACTGGATCAAATGNN
NNNCNGATGNANCTACNC
NNTNTTGGTGGNNTTNNAGATTANNCCGGNAG
TCCAANGCCCNNTTAANA
ACNNACCCNANTTGGNNNNNNNNGNNNNNNN
NNCCNNNNGNTTGAAAANN
NNNNCCANGGNANCCGGGGGNTTCCNNANNC
NNNTNNNNNNCNAANTNCC
79
NNTTGGTNCCNATNNNGNNNNNTNNNANNNN
NNNNGNCNNNCNACCGGNN
NGCACNNGGNNNNNNCTNNTNNAANTGNGTG
GCAAANNNNNNNNNNNNAN
TNNNN
This was performed to ensure the validity of the dsRNA and the sequences were verified using
BLAST nucleotide search tool.
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Supplemental Table 2.3 Total Number of Animals Used for Lifespan Experiments.
Lifespan (Crude Total number of animals at the Total Actual number of animals
extract) beginning of the experiment Censored used
Replicate 1 176 41 135
Replicate 2 176 37 139
Replicate 3 176 42 134
Lifespan Total number of animals at the Actual number of animals
(RNAi) beginning of the experiment Censored used
Replicate 1 176 44 132
Replicate 2 176 39 137
Replicate 3 176 41 135
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Chapter 3: Silencing Fat Metabolism Genes in Parkinson's like Models of Caenorhabditis elegans
3.1 Abstract
Fat metabolism plays an important role in modulating key molecular pathways, such as 
insulin signaling associated with aging. Aging is considered a risk factor for devel oping 
Parkinson's disease (PD). Previous studies in the nematode model of Caenorhabditis elegans 
(C. elegans) show that delaying aging can rescue some of the deleterious PD-like pathologies. 
However, the role of fat metabolism in the pathogenesis of PD is not clear. Using RNA 
interference, we studied the effects of silencing of ‘fat genes' on PD pathology in models of C. 
elegans. We used four candidate genes: nhr-49 and tub-1 (silencing of either one leads to ‘high 
fat' content), and fat-5 and fat-7 (silencing of either one leads to ‘low fat' content) to manipulate 
fat levels in the nematode. The silencing of the fat-5 and fat-7 genes rescued both degeneration 
of dopamine neurons and deficits in dopamine-dependent behaviors, including basal slowing 
and ethanol avoidance in worm models of PD. Similarly, silencing of these genes also decreased 
the formation of protein aggregates in a nematode model of PD expressing α-synuclein in the 
body wall muscles and rescued deficits in resistance to heat and osmotic stress. However, the 
silencing of all four fat genes did not change the total lifespan of any of the models. Overall, 
our research suggests that low fat content can be beneficial in ameliorating PD-like pathology 
and improving functionality, even though it did not extend lifespan.
Authorship for this chapter is as follows: Malabika Maulik, Ajiel Mae Basmayor, Brianna Lu, Swarup Mitra,
Barbara E Taylor and Abel Bult-Ito. Submitted to Human Molecular Genetics.
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3.2 Introduction
Parkinson's disease (PD) is one of the most prevalent age-related neurodegenerative 
diseases causing motor impairments and cognitive dysfunction1. PD usually results in degeneration 
of dopaminergic neurons within the substantia nigra (SN) region of the brain. Such degeneration 
may happen due to the formation of protein aggregates known as Lewy bodies2. Although there 
are treatments available to reduce individual symptoms such as motor deficits, there are currently 
no preventive therapies that can target and lessen PD progression.
Both genetic and environmental factors have been implicated in the pathogenesis of PD3,4.
The α-synuclein (a-syn) gene SNCA was the first to be associated with PD5. Both mutations in 
the SNCA gene and increased copy number result in PD pathology, which is characterized by 
formation of protein aggregates6. The A53T mutation, substitution of threonine for alanine at 
position 53, is linked with the autosomal dominant form of PD5. Exposure to environmental toxins 
such as rotenone, a broad-spectrum insecticide, impairs mitochondrial function and causes 
oxidative stress, causes the death of dopaminergic neurons in the SN and subsequent development 
PD pathophysiology7. Aging is also considered a major risk factor as the number of alterations that 
take place during normal aging have been implicated in the progression of PD8.
Caenorhabditis elegans (C. elegans) offers several advantages for investigating both aging 
and neurodegenerative disease9. These nematode models have been used to characterize protein 
aggregation and dopaminergic neuron degeneration, key molecular hallmarks of PD8. In C. 
elegans, fat metabolism involves a complex and conserved gene network, which regulates food 
sensing and neuroendocrine signaling processes10. Food sensing behavior in worms is also 
controlled by the dopaminergic system, which is also the crucial neural network affected in PD11. 
Despite lack of specific adipocytes, C. elegans shares common human homologues of genes that 
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are implicated in obesity and metabolic disorders10. In mammals, nuclear hormone receptors 
(NHRs), such as peroxisome proliferator-activator receptor protein-alpha (PPARa), are often 
studied as drug targets for lipid metabolism12. One such receptor known as nhr-49 promotes fatty 
acid desaturation and beta-oxidation leading to 'high fat' accumulation on gene silencing, altered 
mitochondrial function and shortened lifespan in nematodes13,14. Like in mammals, mutations in 
tub-1 (tubby homologue) leads to increased fat deposition and increased lifespan in C. elegans15.
Δ9 desaturase enzymes are present in organisms from yeast to humans and are important 
for energy metabolism and lipid synthesis16. Diets high in unsaturated fatty acids decrease 
expression of A9 desaturase and high carbohydrate consumption increases its expression17. In C. 
elegans, A9 desaturases are encoded by the genes: fat-5 and fat-7. RNA interference (RNAi) 
studies with fat-5 and fat-7 have shown that silencing of these genes reduces fat levels in the 
nematodes13. C. elegans is a popular genetic model that allows for easy manipulation of these fat 
metabolism genes using RNAi to create high and low fat content in these organisms. Moreover, 
fatty acid metabolism is known to be involved in stress resistance mechanisms and insulin 
signaling in the worm model18. Such stress resistance mechanisms have been used as a parameter 
to study the effect of aging and insulin signaling in PD models of C. elegans8. However, the direct 
relationship between fat metabolism and PD pathology in nematodes have been sparsely explored.
In this study, we chose to examine the effects of silencing of fat metabolism genes in 
different worm models of PD. Silencing these candidate genes manipulated the level of fats in the 
nematodes. Using this genetic approach, we examined the effects of high and low fat content on 
α-synuclein protein aggregation (wild-type and A53T mutation) and dopaminergic neuron 
degeneration in C. elegans. In addition, we also studied the overall effects on lifespan, health span 
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and stress mechanisms. We hypothesized that that silencing of fat-5 and fat-7 gene will improve 
the pathophysiology and rescue several deficits present in worm models of PD.
3.3 Materials and Methods
3.3.1 C. elegans Strains and Maintenance
Strains used for the study were OW13 (Punc54: a-syn) and TG2435 (pDAT::GFP), which 
were acquired from the Caenorhabditis Genetics Center (University of Minnesota). The other 
strains for the study, i.e., JVR203 (pDAT::mut A53T- a-syn) and JVR208 (pDAT:: WT- a-syn), 
were kindly donated by Drs. Shohei Mitani and Jeremy Van Raamsdonk. The OW13 strain 
expresses human wild-type α-synuclein in its body wall muscle. The JVR203 and JVR208 strains 
express human wild-type and mutant A53T α-synuclein, respectively, in the dopaminergic 
neurons.
The animals were cultured on nematode growth medium (NGM) plates using standard 
procedures19 and maintained at 20 °C. The plates were seeded with Escherichia coli strains OP- 
50-1 or HT115 depending on the experiments. Synchronous populations were created using the 
standard egg lay method (allowing 20-30 animals to lay eggs for 4-6 h and then removing the 
adults) or by hypochlorite treatment (2 % sodium hypochlorite in 0.5 M NaOH). All experimental 
plates (except for fecundity studies) contained 0.04 μg/ml fluorodeoxyuridine (FUdR) for progeny 
control.
3.3.2 RNA Interference
RNAi plates were prepared using isopropyl βD-thiogalactoside (IPTG) and 4X 
concentrated HT115 bacteria for each gene target (L4440, fat-5, fat-7, nhr-49 and tub-1) and 
covered with foil to protect from light20,21. For each replicate of the experiment, control 
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experiments were performed to compare the mechanosensory touch function between mec-7 
silenced to empty vector (L4440)22 groups, to ensure that the RNAi procedure worked properly 
(Supplemental Fig. 1). Nile red staining was done to measure the fat content of the worms 21.
3.3.3 Rotenone Administration
Rotenone (Sigma; 4 μM) in DMSO was added to bacteria-seeded NGM plates 23. Larval 
L4 worms were then loaded onto the rotenone-coated plates until further experimentation. An 
equal volume of DMSO bacteria-seeded NGM plates were used as vehicle controls.
3.3.4 Lifespan Analysis
Following egg lay, synchronous populations of 22 L4 animals were transferred into two 
replicates of each treatment. The survival was determined daily by visual observation under 
dissecting microscope or by gentle prodding with a platinum wire. 'Bagged' animals and animals 
crawling off the plates were censored24. Each experiment was repeated at least 3 times.
3.3.5 Body Bends
Body bends were measured in Day 3 adult worms by counting forward and complete 
sigmoidal movement of the nematodes for 1 min8. Spontaneous reversals were excluded.
3.3.6 Fecundity
Fecundity or viable progeny count was performed by plating Day 2 adults (peak fecundity) 
on fresh treatment plates25. The eggs laid by the adults were allowed to hatch and develop at 20 °C 
for 48 h. The number of progenies produced was manually counted under a dissecting microscope.
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3.3.7 Pharyngeal Pump Rate
The pharyngeal pump rate was assessed by manual counting in pharyngeal compressions 
for 30 s in Day 3 adult worms by placing them on a seeded NGM assay plates25.
3.3.8 Stress Resistance Assays: Heat Stress and Osmotic Stress
Sensitivity to heat stress was determined by assessing survival of young adult worms 
incubated at 35 °C26. Survival was assessed after four hours. Sensitivity to osmotic stress was 
determined by transferring young adult worms to NGM plates containing 500mM concentration 
of NaCl8. The survival of worms was determined after 24 h. Both stress assays were conducted on 
Day 3 of adulthood. The survival was determined by visual observation of motility under 
dissecting microscope or by gentle prodding with a platinum wire. The worms who failed to move 
on prodding were counted as dead.
3.3.9 Dopamine Dependent Behaviors
3.3.9.1 Basal Response to Food
Day 3 worms were washed in M9 buffer and transferred to either unseeded NGM plates or 
NGM plates seeded with OP50-1 bacteria over the entire plate. After 3 min of acclimatization, the 
rate of movement was assessed by counting body bends for 30 s8. Basal slowing was calculated as 
the (rate of movement off food - rate of movement on food) / rate of movement off food8.
3.3.9.2 Ethanol Avoidance Assay
Day 3 adult worms were transferred to the center of NGM plates divided into four 
quadrants: two quadrants seeded with 40 μl ethanol and two others contained no ethanol. After 
30min, the worms were scored for their presence in each quadrant. Ethanol avoidance was 
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assessed as (number of worms in control quadrants - number of worms in ethanol seeded 
quadrants)/ total number of worms8.
3.3.11 Statistical Analysis
The Kaplan-Meier log rank analysis for lifespan survival experiments was performed with 
SPSS (Version 22, IBM, Inc.). All other statistical analyses were performed with Graph Pad Prism 
7 (GraphPad Software, Inc). Treatment effects among groups were assessed using one-way or two­
way analysis of variance (ANOVA). Pairwise comparisons to identify significant differences 
between treatment groups were tested using Tukey's post hoc tests.
3.4 Results
3.4.1 Silencing of fat-5 and fat-7 Genes Ameliorated α-synuclein Overexpression and Improved 
Dopamine-related Behaviors in Transgenic Models of C. elegans
At day 7 of adulthood, silencing of fat-5 and fat-7 genes significantly reduced human wild­
type α-synuclein expression in the OW13 model (Figs. 3.1A and 3.1B) by about 30% (F4,145 = 
15.89, p<0.0001) when compared to the L4440 control (p<0.0001 and p<0.0001, respectively). 
There were no significant differences among control, nhr-49 and tub-1 groups (p>0.05).
At day 3 of adulthood, dopaminergic functions were tested in another transgenic model 
(Figs. 3.1C and 3.1D), JVR208, in which human wild-type α-synuclein was expressed 
specifically in dopaminergic neurons. Basal slowing was increased significantly (F4,70 = 16.5, p 
<0.0001) in both fat-5 and fat-7 treated animals when compared to the L4440 control group 
(p<0.0008 and p<0.007, respectively). Similarly, the ethanol avoidance index was significantly 
increased (F4,10 = 6.884, p<0.001) in animals in the fat-5 and fat-7 groups compared to the empty 
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vector control (p<0.008 and p<0.03, respectively). There were no significant differences among 
control, nhr-49 and tub-1 groups (p>0.05) for either of the behaviors.
3.4.2 Genetic Silencing of fat-5 and fat-7 Genes Improved Resistance to Heat in a Human Wild­
type α-synuclein Overexpression Model of C. elegans
Following RNAi treatment with the candidate fat metabolism genes in a human wild-type 
α-synuclein overexpression model of C. elegans, no significant effects (p>0.05) were observed on 
the overall lifespan (Fig 3.2A), the number of body bends per second (Fig. 3.2D), and osmotic 
tolerance (Fig. 3.2E). Silencing the nhr-49 and tub-1 genes significantly reduced peak fecundity 
(F (4,45) = 5.777, p<0.001) compared to the L4440 control (Fig 3.2B; p<0.003 and p<0.0009, 
respectively). The pharyngeal pump rate was significantly increased (F4,45 = 3.124, p<0.001) in 
the fat-7 group compared to the L4440 control group (Fig. 3.2C; p<0.04). The fat-5 group showed 
significantly increased (F4,10 = 8.4, p<0.001) heat tolerance compared to the L4440 group (Fig. 
3.2F; p<0.002), while the fat-7 group showed a strong trend in improving heat tolerance (Fig. 3.2F; 
p<0.06).
3.3.10 Microscopy and Image Quantification
All images of dopaminergic neuron degeneration were acquired with an Axiovert FX100 
fluorescent microscope and all images of protein overexpression were acquired with a Zeiss 
LSM 510 laser scanning confocal microscope. Magnification and exposure settings were kept 
constant for each microscope. Images were analyzed with ImageJ (National Institutes of 
Health). The α-synuclein levels were quantified based on measurement of total fluorescence. 
Dopaminergic neuron degeneration was quantified on the basis of scoring animals for presence 
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of normal and abnormal neurons. Any neuron with missing soma or dendrite, or with any 
morphological alterations like outgrowths or blebs were considered abnormal27,28.
3.4.3 Genetic Silencing of fat-5 and fat-7 Genes Improved Dopaminergic Neuron Degeneration 
and Related Behaviors in a Model of C. elegans Expressing Human Mutated α-synuclein (A53T 
Mutation)
Genetic silencing of fat-5 and fat-7 genes in a model of C. elegans expressing human 
mutated α-synuclein (A53T mutation) significantly increased the percentage of normal 
dopaminergic neuron morphology in C. elegans (F4,10 = 11.27, p<0.001) expressing human 
mutated α-synuclein in their dopaminergic neurons at Day 7 of adulthood (Fig 3.3A and 3.3B) 
compared to the L4440 control group (p<0.02 and p<0.02, respectively). When compared to the 
L4440 control group, both fat-5 and fat-7 groups showed significantly increased basal slowing 
behavior (F4,70 = 6.7, p<0.001) (Fig. 3.3C; p<0.003 and p<0.0007, respectively) and ethanol 
avoidance index (F4,10 = 15.33, p<0.01) (Fig. 3.3D; p<0.0007 and p<0.002, respectively) . 
Silencing of the nhr-49 and tub-1 genes (Fig. 3.3) had no significant effects on either 
dopaminergic neuron health (p>0.05) or its associated functional behaviors (p>0.05).
3.4.4 Defects in Stress Resistance was Improved by Silencing of fat-5 and fat-7 Genes in C. 
elegans Expressing Human Mutated α-synuclein (A53T Mutation)
Silencing of the four fat genes in a model of C. elegans expressing human mutated a- 
synuclein (A53T mutation) had no significant impact (p>0.05) on the overall lifespan, (Fig. 3.4A), 
the pharyngeal pump rate (Fig. 3.4C) and the number of body bends per second (Fig. 3.4D). 
Silencing the nhr-49 and tub-1 genes significantly reduced peak fecundity compared to the L4440 
control group (F4,45 = 21.71, p<0.001) (Fig 3.4B; p<0.0002 and p<0.0002, respectively). The heat 
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tolerance was significantly increased in the fat-5 and fat-7 groups compared to the L4440 control 
group (F4,10 = 8.78, p<0.002) (Fig 3.4E; p<0.002 and p<0.005, respectively). Silencing of the fat- 
5 and fat-7 genes also significantly increased osmotic tolerance compared to the L4440 control 
group (F4,10 = 35.65, p<0.001) (Fig 3.4F; p<0.0002 and p<0.0002, respectively).
3.4.5 Dopaminergic Degeneration and Related Behaviors were Rescued by Silencing fat-5 and fat- 
7 Genes in a Rotenone-induced Model of C. elegans
There was significant rotenone treatment (F1,20 = 231.2, p<0.0003), RNAi treatment (F4,20 
= 9.925, p<0.0001) and interaction (F4,20 = 14.07, p<0.0001) effects observed for dopaminergic 
degeneration at day 7 of adulthood (Fig. 3.5A and 3.5B). The L4440 (p<0.001), nhr-49 (p<0.02) 
and tub-1 (p<0.05) groups had significant neuronal degeneration after rotenone treatment 
compared to their vehicle control groups. However, there were no significant differences between 
rotenone and control groups for fat-5 (p>0.5) and fat-7 (p>0.5) genetic treatments, which explains 
the significant interaction effect.
Significant rotenone treatment (F1,20 = 29.64, p<0.003), RNAi treatment (F4,20 = 6.064, 
p<0.001) and interaction (F4,20 = 3.295, p<0.04) effects were found for basal slowing behavior 
(Fig. 3.5C). Rotenone treatment significantly reduced basal slowing in all groups except in the fat- 
5 (p>0.5) and fat-7 (p>0.5) groups. Rotenone treatment did not have any negative effect on nhr- 
49 (p>0.5) and tub-1 (p>0.5) groups compared to their vehicle control groups,
For the ethanol avoidance index, significant rotenone (F120 = 8.736, p<0.0001), RNAi 
treatment (F4,20 = 5.509, p<0.008) and interaction (F4,20 = 20.08, p<0.004) effects were observed 
(Fig. 3.5D). Animals in the L4440 (p<0.0003), nhr-49 (p<0.02) and tub-1 (p<0.002) groups 
showed significant reductions in the ethanol avoidance index compared to their vehicle control 
groups. However, there were no significant differences between rotenone and vehicle control 
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groups for fat-5 (p>0.5) and fat-7 (p>0.5) genetic treatments, which explains the significant 
interaction effect. Even though the rotenone dosage did not have any negative effect on nhr-49 
(p>0.5) and tub-1 (p>0.5) groups compared to their vehicle control groups, the total scores for 
both these groups were significantly lower than the rotenone treated fat-5 (p<0.01) and fat-7 
(p<0.01) groups.
3.4.6 Lifespan or Healthspan Measures were Unaltered by Silencing of Fat genes in the Rotenone- 
induced Model of C. elegans
Significant rotenone treatment effects were found for the overall lifespan (Fig. 3.6A; F1,20 
= 59.65, p<0.0001) and fecundity (Fig. 3.6C; F1,40 = 144.8, p<0.004), while not significant for the 
pharyngeal pump rate (Fig. 3.6B; p>0.1) and number of body bends per s (Fig. 3.6D; p>0.1). The 
RNAi treatment, and interaction between rotenone treatment and RNAi treatment effects were not 
significant for lifespan (p>0.1), pharyngeal pump rate (p>0.1), peak fecundity (p>0.1), and number 
of body bends per second (p>0.1). After rotenone treatment, the lifespan of all the RNAi groups 
were significantly reduced compared to the untreated controls (p<0.05), without significant 
differences among the RNAi groups (p>0.05). Similarly, rotenone administration reduced the total 
progeny produced for all the RNAi groups compared to the vehicle control groups (p<0.0001), 
without significant differences among the RNAi groups (p>0.05).
3.5 Discussion
Age being the greatest risk factor for neurodegenerative disorders like PD leads to 
pathological changes in brains such as loss of neurons, oxidative stress, and reduced protein 
degradation to name a few29. Fat metabolism plays an important role in cell physiology and 
molecular signaling30. PD is often characterized by dysfunction of cell homeostasis and energy 
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metabolism31. Recent research also shows the role of insulin in neuronal growth and survival and 
how insulin signaling can impact PD32. Though there has been extensive research on the molecular 
mechanisms leading to cell death in PD pathology, the role of fat metabolism in influencing such 
molecular hallmarks is not clear. In C. elegans, aging is represented by healthspan measures which 
resembles humans33. This includes reduced pharyngeal pump rate, decline in motility and fertility 
and changes in neuromuscular junction34. Moreover, environmental stress responses, such as heat 
shock and osmotic stress, have been used in nematodes to unravel genetic machineries of many 
diseases35. The transgenic PD models of C. elegans have shown to have deficits in the form of 
reduced lifespan, healthspan and increased sensitivity to environmental stressors8. These 
parameters were also used as parameters to characterize aging in our study. Through genetic 
manipulation, we for the first time demonstrate how silencing of fat-5 and fat-7 in worms can 
improve key features of PD: protein aggregation, neuronal degeneration and dopamine-dependent 
behaviors.
Like others 8’23, our experiments showed how expression of a toxic protein (α-synuclein) 
or using a neurotoxin (rotenone) to induce dopaminergic degeneration in C. elegans can modify 
dopaminergic functions or healthspan and make them stress sensitive. We also demonstrated that 
silencing of fat-5 and fat-7 genes resulted in lower fat content (Supplemental Fig. 3.2). Most 
strikingly, our study highlighted that such genetic manipulation of fat-5 and fat-7 genes was 
beneficial for the PD worm strains (wild-type or mutated α-synuclein or toxin-induced model). 
Silencing these genes reduced α-synuclein overexpression and protected against neuronal damage. 
In addition, it also improved dopamine-dependent behaviors, including basal slowing and ethanol 
avoidance in the nematodes. Previous studies have recognized multiple genes and pathways that 
are able to suppress aggregate formation36, protect from dopamine-mediated toxicity37 and regulate 
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cell death in DA neurons28,38. Interestingly, the association between fat metabolism and these 
degenerative molecular pathologies in worm models has not been previously explored. This 
exploration of a connection between genes that regulate fat metabolism and physiological 
assessments of PD symptoms in established C. elegans models has yielded interesting results, and 
our studies now add fat content and specific fat genes to these protective mechanisms.
Research shows that stress-resistance mechanisms are controlled by fatty acid 
metabolism18. Moreover, PD models can have different sensitivity towards different stressors8. 
Our research showed that RNAi of fat-5 and fat-7 increased heat tolerance in protein 
overexpression (both wild-type and A53T α-synuclein) models of C. elegans probably due to 
reduced unsaturated fats which are known to impact thermotolerance18. This was also shown to 
improve osmotic tolerance in A53T α-synuclein model but not in the wild-type α-synuclein strain. 
These differential effects might be attributed to varying changes in the mitochondrial proteome 
and function due to different protein expression (wild-type vs mutated)39. Such altered 
mitochondrial function is often considered as a key factor for osmotic stress adaptation40.
Silencing of the nhr-49 and tub-1 genes significantly reduced ethanol avoidance behavior 
only in the wild-type strain, TG2435. In mammals, PPARa, a nhr-49 homologue, is known to 
negatively modulate dopamine cell activity41. Moreover, ethanol avoidance in worms is regulated 
by both dopamine and serotonin and such an environmental response is co-dependent on olfactory 
neurons42. Our results also show that only silencing tub-1 (and not nhr-49) increases fat levels in 
the adult worms. A previous study indicates that fat content due to silencing of nhr-49 may depend 
on the age of worms13. Genetic manipulation of both these genes led to reduced fertility in protein 
overexpression worm models13. However, silencing of either of these genes had no effect on a- 
synuclein protein overexpression strains (both wild-type and A53T). One of the limitations of our 
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study is that we did not create mutants by deleting these candidate genes. We rather chose to 
genetically silence the genes and reduce gene expression levels rather than completely deactivating 
them. Therefore, for follow up studies it would be interesting to assess whether complete deletion 
of these fat metabolism genes have the same effects on the tested end points used in the study.
Finally, results from our research reveal that that silencing of fat-5 and fat-7 may influence 
neuronal health or protein expression greatly, while the effects on lifespan and general health can 
be marginal to none. Cooper et al. have primarily used lifespan as the key parameter for measuring 
anti-aging interventions8. However, there are studies who have clearly shown that lifespan and 
healthspan can be considered as different events in organisms and increased lifespan often is 
accompanied by frail health43. This could explain our differences in results where none of the fat 
genes had any impact on longevity of the PD models. Hence, based on our results we may conclude 
that modulating lifespan should not be the sole focus for anti-aging treatments, especially for 
therapeutic options of age-related disorders such as PD.
3.6 Conclusion
Overall, our results show that silencing of fat-5 and fat-7 genes, which results in reduced fat 
content, can improve a diseased pathology by reducing toxic protein expression and rescuing 
neuronal loss in the nematode models. However, it also poses further questions on the intricate 
interplay between fat metabolism pathways and neurodegenerative disorders.
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3.8 Figures
Figure 3.1 Silencing of fat-5 and fat-7 Genes Reduced Human Wild-type α-synuclein 
Overexpression and Dopamine-related Behaviors in Models of C. elegans.
Graphical representation of (A) fluorescence intensity of the OW13 (n=20-30 animals per group), 
(C) basal slowing and (D) ethanol avoidance of JVR208 animals (n=10-15 animals per group) fed 
on different genetic RNAi treatments (L4440, fat-5, fat-7, nhr-49 and tub-1). The empty vector 
L4440 was considered the control. (B) Representative confocal images of the α-synuclein/YFP 
expression in the head region of day 7 OW13 adults. Magnification is 40X and scale bar is 50 μm. 
The data represent the mean ± SEM with significant differences between the control and treatments 
at *p<0.05, **p<0.001 and ***p<0.0001. Each experiment was repeated three times.
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Figure 3.2 Genetic Silencing of fat-5 and fat-7 Genes Conferred Heat Resistance in a Human Wild­
type α-synuclein Overexpression Model of C. elegans.
Graphical representation of (A) mean lifespan (n=44 animals per group), (B) peak fecundity, (C) 
pharyngeal pump rate, (D) body bends, (E) osmotic stress and (F) heat tolerance of JVR208 
animals (n=10-15 animals per group) fed on different genetic RNAi treatments (L4440, fat-5, fat- 
7, nhr-49 and tub-1). Empty vector L4440 was the control treatment. The data represent the mean 
± SEM with significant differences between the control and treatments at *p<0.05 and **p<0.01. 
Each experiment was repeated three times.
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Figure 3.3 Silencing of fat-5 and fat-7 Genes Rescued Dopaminergic Degeneration and Related 
Behaviors in a Model of C. elegans Expressing Human Mutated α-synuclein (A53T Mutation).
Graphical representation of (A) percentage of normal dopaminergic neurons (n=25-30 animals per 
group), (C) basal slowing and (D) ethanol avoidance behaviors (n=10-15 animals) in JVR203 
animals fed on different genetic RNAi treatments (L4440, fat-5, fat-7, nhr-49 and tub-1). Empty 
vector L4440 was the control treatment. The data represent the mean ± SEM with significant 
differences between the control and treatments at *p<0.05, **p<0.01 and *** p<0.001. Each 
experiment was repeated three times. (B) Representative images of dopaminergic neurons with 
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outgrowths and blebs. Any neurons having either of these morphological features were considered 
as not normal. Magnification is 40X and scale bar is 100 μm.
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Figure 3.4 Defects in Stress Resistance was Ameliorated by Silencing of fat-5 and fat-7 Genes in 
C. elegans Expressing Human Mutated α-synuclein (A53T Mutation).
Graphical representation of (A) mean lifespan (n=44 animals per group), (B) peak fecundity, (C) 
pharyngeal pump rate, (D) body bends, (E) heat stress and (F) osmotic stress of JVR208 animals 
(n=10-15 animals per group) fed on different genetic RNA interference treatments (L4440, fat-5, 
fat-7, nhr-49 and tub-1). Empty vector L4440 was the control treatment. The data represent the 
mean ± SEM with significant differences between the control and treatments at *p<0.05, **p<0.01 
and ***p<0.001. Each experiment was repeated three times.
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Figure 3.5 Silencing of fat-5 and fat-7 Genes Rescued Dopaminergic Degeneration and Associated 
Behaviors in a Rotenone Induced Model of C. elegans.
Graphical representation of (A) percentage of normal dopaminergic neurons (n=25-30 animals per 
group), (C) basal slowing and (D) ethanol avoidance behaviors (n=10-15 animals) in TG2435 
animals fed on different genetic RNA interference treatments (L4440, fat-5, fat-7, nhr-49 and tub-
1) and rotenone (0 and 4μM). Empty vector L4440 was the control treatment. The data represent 
the mean ± SEM with significant differences between the rotenone treated and untreated groups at 
*p<0.05, **p<0.01 and *** p<0.001. Each experiment was repeated three times. (B) 
Representative images of dopaminergic neurons with rounding neurons or axons with blebs or 
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missing dendrites. Any neurons having either of these morphological features were considered as 
not normal. Magnification is 40X and scale bar is 50 μm.
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Figure 3.6 Lifespan or Healthspan Measures were Unaltered by Silencing of fat-5 and fat-7 genes 
in Rotenone-induced Model of C. elegans.
Graphical representation of (A) mean lifespan (n=44 animals per group), (B) pharyngeal pump 
rate, (C) peak fecundity and (D) body bends of TG2435 animals (n=8-10 animals per group) fed 
on different genetic RNA interference treatments (L4440, fat-5, fat-7, nhr-49 and tub-1) and 
rotenone (0 and 4□DM). Empty vector L4440 was the control treatment. The data represent the 
mean ± SEM with significant differences between the control and rotenone treatments at #p<0.05, 
**p<0.01 and ***p<0.001. Each experiment was repeated three times.
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Supplemental Figure 3.1 Graphical Representation of the Touch Response as a Measure of Batch 
Control for the RNAi Plates.
The worms (n=10 per group) were grown on two different RNAi treatments: L4440 and mec-7. 
Treatment with mec-7 showed significantly diminished mechanosensory touch response compared 
to the L4440 control (***p<0.001).
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Supplemental Figure 3.2 Lipid Staining to Validate the Effect of Silencing of Fat Metabolism 
Genes
(A) Confocal images and (B) graphical representation of the Nile red staining as a measure of total 
fat content in TG2435 Day 3 worms after gene silencing of fat metabolism genes. The worms 
(n=12-13 per group) were grown on different RNAi treatments: L4440, fat-5, fat-7, nhr-49 and 
tub-1 genes. Treatment with fat-5 and fat-7 genes showed significantly lower fat content compared 
to the L4440 control (**p<0.01 and * p<0.05 respectively). Treatment with tub-1 shows 
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significantly higher fat content than the L4440 control (**p<0.01). The experiment was repeated 
twice. Scale bar is 200 μm.
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Chapter 4: Complex Interaction of Dietary Fat and Alaskan Bog Blueberry Supplementation 
Influences Manganese Mediated Neurotoxicity and Behavioral Impairments.
4.1 Abstract
Dietary fat is known to modulate neuronal health that contributes to age related nervous system 
disorders. However, the complex interaction between dietary fat and supplementation and its 
consequences on neurotoxic pathophysiology has been sparsely explored. The indigenous Alaskan 
bog blueberry (BB), Vaccinum uliginosum, is known to have anti-inflammatory properties, mostly 
attributed to its rich polyphenolic content. Here, we evaluate the interplay between dietary fat and 
BB supplementation in a sub-chronic manganese (Mn) exposure that inflicts neurotoxicity and 
behavioral impairments. When supplemented with BB, both low-fat and normal-fat diet 
ameliorated the behavioral and the molecular hallmarks of Mn-induced neurotoxicity. On the 
contrary, high-fat diet was found to exacerbate these Mn-induced pathological features. 
Furthermore, BB supplementation failed to recover the aggravation catalyzed by high fat diet in 
Mn-treated mice. Overall, our results demonstrate the importance of including dietary regimen 
comprising polyphenolic rich supplements with low-fat content in combating age related 
neurodegenerative disorders.
Authorship for this chapter is as follows: Malabika Maulik, Swarup Mitra, Mckenzie Sweeney, Brianna Lu, 
Barbara E Taylor, and Abel Bult-Ito. Submitted to Journal of Functional Foods.
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4.2 Introduction
Manganese (Mn) is an essential trace metal which governs physiological processes that 
support healthy growth, development and brain function (1). Particularly, Mn is essential for 
maintaining redox status, energy balance and metabolism of key biomolecules, including proteins, 
lipids and carbohydrates (1). Additionally, Mn functions as a cofactor for crucial enzymes such as 
pyruvate carboxylase, arginase and Mn-superoxide dismutase, which are required for synthesis of 
neurotransmitters as well as functioning of neuronal and glial cells in the brain (2). However, 
excessive and chronic exposure to Mn results in pathological alterations in the brain, particularly 
in the striatal pallidum and substantia nigra (SN) accompanied by loss of dopaminergic neurons 
(3). Mn induced toxicity and degeneration includes motor dysfunction similar to those observed 
in Parkinson's disease (PD) (4). The symptoms include gait imbalance, rigidity, tremors, dystonia, 
and bradykinesia (5). Studies have elucidated the role of neuroinflammatory factors, such as, nitric 
oxide synthase 2 (iNOS), that aggravate neuronal injury due to Mn exposure via microglial 
activation (6). Additionally, in vitro studies have demonstrated that such Mn-induced 
inflammatory microglial activation can result from and interaction with signaling pathways 
involving nuclear factor kappa B (NF-κB) (6).
Since environmental factors play a critical role in age-related neurodegenerative disorders, 
it is imperative to examine the concerted action diet and supplementation play in the disease 
etiology and progression. Previous research indicates that long term consumption of high fat in the 
diet has been linked to increased inflammation and oxidative stress in the brain (7). A high fat diet 
(HFD) leads to increased microglial activation (8), which in turn can promote pro-inflammatory 
responses in the brain resulting in impaired neurogenesis and cognitive function, similar to what 
is seen in aging (9). Studies also associate a HFD and reduced neurogenesis because of decreased 
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levels of brain-derived neurotrophic factors (BDNF) (7). A low fat diet (LFD) on the contrary is 
known to be protective against cognitive decline in older subjects (10) and other age-related 
chronic diseases (11). LFDs reduce inflammatory microglial activation in the ageing mouse brain 
(12), upregulate BDNF and enhance neurogenesis (13).
Blueberries (BB) are rich in antioxidant/anti-inflammatory polyphenolic compounds like 
anthocyanins and proanthocyanidins (14). Diets supplemented with such phytochemicals, impact 
the aging brain (15), modulate stress signaling pathways and reduce microglial activation, a key 
marker of inflammatory response (7). Moreover, diets rich in such natural compounds can 
attenuate age-related behavioral deficits (16) and enhance neurogenesis by elevating neurotrophic 
growth factors (17). Indigenous Alaskan botanicals like bog blueberry (BB), Vaccinum 
uliginosum, contain higher amounts of polyphenolic compounds relative to Vaccinum sp. grown 
in temperate regions (18, 20). These endemic species of berries primarily have been beneficial in 
combating age-related cellular symptoms in C. elegans and in in vitro models (19, 20).
The current study aimed at determining and comparing the behavioral effects and underlying 
molecular mechanisms modulated by consumption of different diets in the presence/absence of 
BB supplementation and when introduced to a neurodegenerative toxic insult. We investigated the 
hypothesis that a LFD in the presence of BB will be most neuroprotective among all the diet groups 
in improving behavioral and molecular markers in this metal-induced neurotoxic mouse model. 
Further, HFD will cause decline in behavioral measures and result in increased neurotoxic 
responses in the animals compared to the ones fed with a LFD and a NFD. Based on a previous 
study (7), it was also postulated that BB supplementation will alleviate the deficits induced by a 
HFD in this metal-induced neurotoxic mouse model.
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4.3 Materials and Methods
This project was conducted as per the University of Alaska Fairbanks Institutional Animal Care 
and Use Committee approved animal care and experimental procedures (IACUC assurance 
number 1024315).
4.3.1 Experimental Animals
Three month old C57BL6/J male mice were obtained from Jackson Laboratory (Bar Harbor, ME, 
USA) and were housed in groups of 4 in a 12:12 L:D cycle. Mice were given two weeks to 
acclimatize before introducing them to the experimental regimen.
4.3.2 Experimental Design
Following the two week acclimatization period, mice were placed on one of the six diets and 
fed ad libitum for a period of four months (n =24-26 animals per diet). The diets comprised of 
NFD, LFD, HFD, NFD + 5% BB, LFD + 5% BB and HFD + 5% BB. Alaskan bog blueberries 
were collected from interior Alaska and freeze dried. Freeze dried berries were crushed into a 
powder and shipped to LabDiet (St Louis, MO) where they were added to food pellets at 5% of 
the total pellet weight. The diet compositions are included in Table 4.2.
After four months on the diet, the mice were subjected to vehicle and subcutaneous 
manganese injections (n=12-13 animals per diet and injection group) on every other day for a total 
of 3 injections. We used a sub chronic dosage of manganese chloride (MnCh) that is known to 
inflict a neurotoxic state that often precedes neurodegeneration (6, 21, 22). Twenty-four hours after 
the last injection, mice were subjected to a series of behavioral tests comprised of the open field 
test on day 1 to measure anxiety-like behavior and locomotor activity, the novel object recognition 
test on day 3 to measure short term memory, and the cylinder test on day 5 and parallel rod floor 
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test on day 7 to measure locomotor agility (Fig 4.1). All data were collected by experimenters 
blinded to the study design and hypothesized outcomes.
4.3.3 Drugs
MnCl2 was purchased from Sigma-Aldrich (Catalogue no. 203734) and dissolved in 0.9% sterile 
physiological saline (pH=7.4). Sterile saline was used as vehicle for control groups. Animals in 
the manganese treatment group received subcutaneous injections of 50 mg/kg MnCl2 for three 
days (day 1, day 3 and day 5). The vehicle group received saline injections on the same days. 
Injection volume of 0.3 mL per 40 g mouse was adjusted proportionally according to the body 
weight of the animals.
4.3.4 Behavioral Tests
4.3.4.1 Open Field
Animals were assessed for anxiety-like behavior and locomotor activity in the open field test 
(23). Animals undergoing testing were transported in home cages and were housed outside the 
testing room prior to testing. The open field apparatus consisted of an arena (40 cm x 40 cm x 30 
cm) with opaque plexiglass walls. Testing was conducted for a 3-min duration (24-26). Animals 
were individually placed in the center of the field and allowed to explore the arena. The total 
number of central entries into the central zone was evaluated as an anxiety-like measure (24). Total 
distance traveled was used to assess locomotor activity (27). All experimental parameters were 
recorded by the ANYMaze video tracking system (Stoelting Co., Wood Dale, IL, USA). The 
apparatus was cleaned with a dilute chlorhexidine solution and dried before each test.
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4.3.4.2 Novel Object Recognition
The novel object recognition test was performed to evaluate object recognition memory (28). 
Mice were trained in the open field arena (40 x 40 x 30 cm). The mice were given an opportunity 
to explore the open field arena without objects present for 3 min. Twenty-four hours later, the 
training comprised of allowing the mice to explore two identical objects (plastic toys) within a 5 
cm distance for 3 min with the ANYMaze video tracking program (Stoelting Co.). Mice were then 
removed from the apparatus and returned to their home cages for 4 hours. After four hours, one of 
the objects was replaced with a novel object of different shape and size. In the testing phase mice 
were reintroduced into the apparatus for 3 min to investigate the familiar and the novel object. 
Time spent exploring the familiar and novel objects were recorded. The preference of one object 
over another was assessed through the recognition index (RI), which is determined by the time 
spent on the novel object relative to the time spent on both novel and familiar objects: [RI 
= TN/(TN + TF)] where TN is time spent on the novel object and TF is time spent on the familiar 
object (29). Objects and exploration arena were cleaned with a dilute chlorhexidine solution after 
each animal.
4.3.5.3 Cylinder Test
Forelimb locomotor asymmetry was measured with the cylinder test. Mice were placed in a 
glass cylinder (8 cm in diameter and 12 cm in height) for 3 minute duration. The number of wall 
contacts with both the forelimbs together was counted and a lower number indicated a larger level 
of forelimb locomotor asymmetry (30).
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4.3.6.4 Parallel Rod Floor
The parallel rod floor apparatus was used to measure motor coordination in the mice (31). Mice 
were placed in a 20 x 20 cm acrylic box with a floor made of steel rods spaced 8mm apart from 
each other. The floor of the box was raised at a height of 1 cm above a base steel plate. The total 
testing time was for 15 min during which motor coordination deficits were assessed by the total 
number of paw slip errors normalized to the distance travelled. The parameters were calculated 
through the AnyMaze behavioral acquisition software. The apparatus was cleaned with 70% 
ethanol after each animal.
4.3.5 Brain Tissue Collection and Molecular Analysis
4.3.5.1 Perfusion and Brain Sectioning
Twenty-four hours after the last behavioral assessment mice (n=4-5 from each of 12-13 per 
treatment groups) were subjected to whole body transcardial perfusion with 4% paraformaldehyde 
in phosphate buffered saline (PBS), following a rinse with PBS to remove the blood (32, 33) . 
Brains collected after perfusion were fixed overnight in 4% paraformaldehyde. Fixed brains were 
then transferred to 30% sucrose solution in PBS and stored at 4 °C until they submerged 
completely. Brains were then placed in Tissue-Tek OCT compound in beaker cups (VWR 
International) and frozen in chilled hexane. Coronal sections of 20 pm between -4.84 Bregma and 
-5.02 Bregma were obtained from the frozen brains on a freezing microtome (Leica CM1900) as 
per the mouse brain atlas. Brain slices on gelatin coated slides (VWR Cat. no. 48311-703) were 
then stored at -20 °C until further use.
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4.3.5.2 Nissl Staining
Slides containing brain sections were kept on a slide drier for 20 minutes. The slides were dipped 
in 100% alcohol (twice for 5 min) followed by 70 % alcohol (twice for 5 min). Samples were 
stained with a 0.1% warm Cresyl Violet solution (37 °C) for 3-10 mins. The slides were washed 
in distilled water and subjected to dehydration in 95% and 100% alcohol (twice for 5 min each). 
Finally, the slides were cleared with xylene and mounted with vectamount. The slides were 
visualized and the total number of stained cells in the substantia nigra pars compacta were counted 
using the ImageJ software (NIH) cell counter.
4.3.5.3 Immunohistochemistry
Slides containing brain sections were first washed in PBS (five 5-min washes). The slides were 
then incubated in 30% hydrogen peroxide in PBS for 30 min at room temperature followed by 
PBS washes (six 5-min washes). Blocking buffer (PBS containing 5% normal goat serum, 2% 
BSA, and 0.4% Triton X-100) was then added to the slides for 1 h. After 1 h, slides were washed 
in PBS (three 5-min washes) and incubated with Tyrosine Hydroxylase (TH) primary antibody 
(Millipore Catalogue AB152; 1:500 in PBS and 0.4% Triton X-100) overnight for 18 hours. On 
day two, slides were washed in PBS (four 5-min washes) and were incubated with secondary 
biotinylated goat anti-rabbit antibody (1:600, Vector laboratories Cat. no. BA1000; in PBS and 
0.04% Triton X-100) for 1 h. Sections were finally processed using the Vectastain Elite ABC 
immunoperoxidase system (Vector Laboratories) as per the manufacturer instructions and 
visualized with Ni2--DAB enzyme substrate. For analysis of TH reactive cells, ImageJ software 
(NIH) was used. All brain sections were analyzed by measuring the optical density of the neurons 
positively for TH in the substantia nigra pars compacta by subtracting the background staining.
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4.3.5.4 Brain Tissue Harvesting
After 24 hours of the last behavioral test, mice from each treatment group were sacrificed 
through cervical dislocation and brains were extracted and snap frozen in liquid nitrogen at 80 °C 
until further processing. Hippocampal and substantia nigra regions were obtained using a 
micropuncher and homogenized in chilled RIPA buffer (with added Proteinase/Phosphatase 
inhibitors cocktail, Roche). Homogenates were then centrifuged at 10,000 g for 10 min at 4 °C. 
The supernatant was collected in fresh Eppendorf© tubes and stored at -80 °C until further 
analysis. Total protein was measured by Pierce BCA kit.
4.3.5.5 ELISA
Total BDNF protein was measured in hippocampal homogenates using a commercially available 
ELISA kit following the manufacturer's protocol (BDNF Emax ImmunoAssay System, Promega 
Southampton, UK, Cat No. G7611), NOS2 (iNOS) and NF-kB levels were measured in the 
homogenates from substantia nigra region using kits from Cloud-Clone Corporation (Catalog 
No. ABIN415396 and ABIN425131, respectively). Finally, Iba-1 levels were measured in the 
substantia nigra region using a kit from Lifespan BioSciences Inc. (Catalog No. LS-F16598). All 
samples were assayed in duplicate (n= 5 per group). Data collection was performed at 450 nm 
using a Biotek EL808 spectrophotometric plate reader.
4.3.6 Statistical Analysis
All statistical analyses were performed in the Statistical Analysis Software (SAS version 9.4, 
Cary, NC). Behavioral assessments were tested in a general linear model (GLM) analysis of 
variance (ANOVA) for the main effects of diet, BB, Mn treatment and interaction effects (diet x
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BB, diet x Mn treatment, BB x Mn treatment and diet x blueberry x Mn treatment). Wherever 
significance was found appropriate post hoc pair-wise comparisons were conducted using the 
studentized range test.
4.4 Results
4.4.1 Alaskan BB Improved OF Locomotor Activity in Mn Treated Animals when Supplemented 
with LFD
There were significant main effects of diet, BB and Mn treatment on the total distance travelled 
by the mice in the open field (Table 4.1 and Fig. 4.2A). The interaction effect between diet and 
BB on the assessed behavior was also significant (Table 4.1 and Fig. 4.2A). In the vehicle groups, 
mice consuming the HFD travelled shorter distances compared to ones in the NFD (t23=3.174, 
p<0.03) and the LFD (t23= 5.664, p<0.0001) groups. In the vehicle groups, animals consuming the 
LFD with BB travelled greater distances compared to ones fed the NFD with BB (t24= 6.756, 
p<0.0001) and the HFD with BB (t22= 2.194, p<0.0002). All animals in on a NFD (t23= 3.88, 
p<0.002), LFD (t23= 3.542, p<0.004) and LFD with BB (t23= 3.432, p<0.005) groups displayed 
reduced locomotor activity after administration of Mn injections when compared to the vehicle 
groups. Mice in the NFD with BB group (t23 = 0.2482, p >0.1), the HFD with (t23 = 1.468, p >0.1) 
and without BB (t22 = 1.387,p >0.1) groups when exposed to Mn were not significantly different 
from the vehicle control groups and showed comparatively reduced locomotor deficits. Also, when 
exposed to Mn, the LFD group without BB was significantly different from the HFD group without 
BB (t22 = 3.468,p < 0.02). In presence of BB, animals treated with Mn in the LFD group travelled 
greater distances compared to the NFD (t22 = 3.369,p < 0.02) and HFD (t22 = 3.651,p < 0.006) 
groups.
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The significant diet and BB interaction effect was due to the mice on the LFD and HFD, both 
in the vehicle and MN treatment groups, tending to travel longer distances with BB treatment 
compared to without BB, while no BB effect was observed in the NFD groups (Fig. 4.2A).
4.4.2 Alaskan BB with LFD Reduced Anxiogenic OF Behavior Inflicted by Mn Insult.
Significant main effects of the diet, BB and Mn treatment on the anxiety-like OF behavior, i.e., 
number of central entries, were found (Table 4.1 and Fig. 4.2B). The interaction effects between 
diet and Mn and diet and BB on the number of central entries were also significant (Table 4.1 and 
Fig. 4.2B). HFD animals were most anxiogenic in comparison to the NFD vehicle group (t23= 
6.342, p<0.0001). Vehicle animals consuming BB with a NFD (t24 = 3.286,p < 0.02) and a LFD 
(t24 = 4.168, p < 0.0009) were less anxiogenic compared to their controls without BB. Mice fed 
with a NFD (t23=6.15, p<0.0001), a NFD with BB (t23=6.646, p<0.0001) and a LFD (t23=3.046, 
p<0.02) scored lower numbers of central entries and hence were more anxious-like after 
administration of Mn injections when compared to their vehicle groups. Animals on a LFD with 
BB (t23 = 0.2482, p >0.1) when exposed to Mn were not significantly different from the control 
group and displayed similar anxiolytic behaviors as the latter. Moreover, in the presence of Mn 
mice on a LFD with BB performed better than the mice on a LFD without BB (t22=4.756, 
p<0.0001). The mice on a HFD with or without BB had the lowest number of central entries 
compared to the mice on the NFD or LFD. In addition, Mn did not affect this anxiety-like behavior 
any further.
The significant diet and Mn interaction effect was due to the mice on the NFD with and without 
BB and on the LFD significantly decreasing the number of central entries after Mn treatment, 
while the mice on the LFD with BB and on the HFD with and without BB did not show a Mn 
effect. The significant diet and BB interaction effect was due to the mice on the NFD and LFD 
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with BB performing better in the OF than the mice on the NFD and LFD without BB, while BB 
treatment had no effect on the mice on a HFD (Fig. 4.2B).
4.4.3 LFD in Combination with Alaskan BB Improved Novel Object Recognition Memory.
Significant main effects of the diet, BB and Mn on the recognition index in OR behavior 
was found (Table 4.1 and Fig. 4.2C). There was also a significant interaction effect between BB 
and Mn treatment (Table 4.1 and Fig. 4.2C) on the memory function test. HFD mice had the lowest 
recognition index in comparison with NFD (t23= 3.971, p<0.002) and LFD (t23= 3.5, p<0.001) 
groups. Animals consuming BB with a NFD (t24 = 4.272,p<0.0006) and a LFD (t24 = 3.427,p < 
0.02) showed enhanced memory compared to their controls without BB. Mice on a NFD 
(t23=3.244, p<0.009), a NFD with BB (t23=7.146, p<0.0001) and a LFD (t23=4.208, p<0.0004) had 
a significantly lower recognition index and had cognitive impairment after administration of Mn 
injections when compared to their vehicle groups. Mice on a LFD with BB (t23 = 1.061,p >0.1) 
when exposed to Mn were not significant different and displayed similar recognition index as the 
vehicle control mice. Also, when exposed to Mn, animals on the LFD with BB group overcame 
the memory deficits and performed better than both mice on a NFD with BB (t22=5.36, p<0.0001) 
and a LFD with BB (t22=6.451, p<0.0001).
The significant BB and Mn interaction effect was due to the mice on the LFD with BB and 
the HFD with and without BB showing no significant effect of Mn treatment, while the mice on 
the NFD with and without BB and on the NFD significantly decreasing the recognition index after 
Mn treatment compared to their vehicle controls (Fig. 4.2C).
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4.4.4 Alaskan BB Ameliorated Mn-induced Sensory Motor Deficits in the Cylinder Test
Significant main effects of the diet, BB and Mn treatment on the sensory motor function in the 
cylinder test, i.e., number of rears, were observed (Table 4.1 and Fig. 4.3A). A significant BB and 
Mn interaction effect was also found (Table 4.1 and Fig. 4.3A) for the number of rears. Mice on a 
HFD had a significant higher sensory motor deficit score, i.e., ataxia index, compared to mice on 
a NFD (t23 = 4.088, p<0.002), with the mice on a LFD having an intermediate rearing score. Mn 
induced sensory defects in mice on a NFD (t23 = 6.468, p <0.0001), a LFD (t23 = 4.834, p <0.0001) 
and a HFD (t22 = 3.77,p <0.001) compared to their vehicle controls. These Mn-induced deficits 
were rescued by BB supplementation for mice on a NFD (t22= 4.219, p<0.0008) and a LFD (t22= 
3.95, p<0.002) compared to the mice not receiving BB. The Mn-induced deficit of mice on a HFD 
was also ameliorated by BB supplementation as the sensory defects of mice on a HFD with BB 
were not significantly different between the Mn and vehicle groups (t22= 2.355, p>0.1).
The significant BB and Mn interaction effect was due to Mn treatment significantly reducing 
the number of rears of the mice on the NFD, LFD, and HFD without BB, while Mn had no effect 
on these mice on the diets with BB (Fig. 4.3A).
4.4.5 Alaskan BB Mitigated Mn-induced Motor Co-ordination Defects in the Parallel Rod Floor 
Test.
Significant main effects of the diet, BB and Mn treatment on the motor co-ordination function, 
i.e., the ataxia index, in the parallel rod floor test (Table 4.1 and Fig. 4.3B). The interaction effects 
between the diet and Mn treatment and between BB and Mn treatment (Table 4.1 and Fig. 4.3B) 
for the ataxia index were also significant. Overall, vehicle treated mice consuming a HFD scored 
higher ataxia index scores compared to mice on a NFD (t23=3.184, p<0.004) and on a LFD 
(t23=1.384, p<0.04). After administration of Mn, all three diets groups: NFD (t23=4.417, p<0.005), 
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LFD (t23=3.528, p<0.004) and HFD (t23=4.991, p<0.0001) showed impaired motor co-ordination 
with higher ataxia index scores compared to their vehicle treated groups. BB improved motor 
coordination because no significant differences were found between vehicle and Mn treated mice 
for all the BB consuming diet groups (NFD: t23= 0.8201, p>0.1; LFD: t23= 0.5526, p>0.1, HFD 
t23= 0.5526, p>0.1). Consumption of BB ameliorated motor dysfunction in the Mn-treated NFD 
groups (t22= 3.737, p<0.005). Similarly, mice on a LFD with BB displayed improved motor 
functions in both vehicle (t24=3.073, p<0.04) and Mn (t22=6.94, p<0.0001) treated groups 
compared to mice on a LFD.
The significant Diet and Mn interaction effect was due to the mice on the NFD and LFD with 
BB significantly reducing their ataxia index after Mn treatment compared to their diet without BB 
groups after Mn treatment, while the mice on the HFD with BB after Mn treatment did not 
significantly differ from their HFD without BB group after Mn treatment (Fig. 4.3B).The 
significant BB and Mn interaction effect was due to all the diet groups without BB significantly 
increasing their ataxia index scores after Mn treatment compared to their vehicle groups, while all 
the diet groups with BB after Mn treatment were not significantly different from their vehicle 
groups (Fig. 3B).
4.4.6 A LFD Diet in Presence of Alaskan BB Elevated BDNF Levels in Mn Exposed Animals
Significant main diet, BB and Mn treatment effects were found for the total BDNF levels in 
the hippocampal region (Table 4.1 and Fig. 4.4A). No significant interaction effects were found. 
Mice on a NFD with BB had elevated hippocampal BDNF levels compared to mice on a NFD 
without BB (t8= 3.314, p<0.03) and a similar trend was observed in the LFD vehicle groups. Mn 
administration reduced the BDNF levels in the LFD without BB group (t8= 3.36, p<0.001) and 
showed a similar trend in the NFD without BB group (t8= 2.447, p<0.1). There was significant 
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difference between control and Mn treated NFD with BB group (t8= 4.319, p<0.0006) group. 
However, after Mn treatment the LFD group with BB showed significantly higher BDNF levels 
than the LFD group without BB (t8= 4.18, p<0.002). There were no significant differences between 
control and Mn treated LFD with BB groups (t«= 1.066, p>0.1). Animals on a HFD had very low 
levels of BDNF compared to mice on a NFD (t8= 1.81, p<0.008) and a LFD (t8= 5.542, p<0.0001). 
But there was no significant difference observed between either BB consuming HFD groups (t8= 
0.035, p>0.5) or between Mn treated HFD without BB and Mn treated HFD with BB group (t«= 
2.569, p>0.1).
4.4.7 Attenuation of Inflammatory Markers by Alaskan BB in Mn Treated Animals
4.4.7.1 Iba1
Significant main BB and Mn treatment effects were found for the total iba1 levels in the SN 
region (Table 4.1 and Figure 4.4B). There was also an interaction effect between BB and diet and 
between BB and Mn treatment on this inflammatory marker (Table 4.1 and Fig. 4.4B). BB 
decreased the iba1 levels in mice on a HFD (t8= 4.561, p<0.0006) only in the vehicle groups. After 
Mn treatment, there was a significant increase in iba1 levels for mice fed NFD (t8= 3.624, 
p<0.005), LFD (t8= 2.814, p<0.05) and HFD with BB (t8= 4.357, p<0.0005). The level of iba1 in 
the NFD with BB group (t«= 3.755, p<0.008) after Mn treatment was significantly lower compared 
to the NFD without BB group. A similar trend was shown in mice on a LFD with BB (t8= 2.959, 
p<0.08) after Mn treatment compared to the non BB treated LFD group.
4.4.7.2 NOS2/iNOS
A significant main BB effect was found for the total NOS2/iNOS levels in the substantia nigra 
region (Table 4.1 and Fig. 4.4C). No significant interaction effects were found. After Mn 
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treatment, mice on a NFD (t8= 3.681, p<0.009) and LFD (t8= 4.106, p<0.003) with BB had lower 
levels of NOS2/iNOS levels compared to their respect diet group without BB. Mn administration 
significant decreased NOS2/iNOS levels in the mice on a LFD with BB compared to the LFD with 
BB vehicle group (t8= 2.948, p<0.03).
4.4.7.3 NF-kB
Significant main BB and Mn treatment effects were found for the total NF-kB levels in the 
SN region (Table 4.1 and Fig. 4.4D). No significant interaction effects were found. The level of 
NF-kB in the SN region of mice on a HFD without BB was significantly higher compared to the 
mice on the HFD with BB (t8= 3.613, p<0.02) only for the vehicle group. In the NFD and LFD 
vehicle groups, BB did not change NF-kB levels compared to their respective without BB groups. 
Mn treatment tended to increase NF-kB levels in the NFD and HFD without BB, while these 
differences were significant for the other comparisons compared to their respective vehicle 
controls; Mn treatment significantly increased NF-kB levels in mice on a NFD with BB (t8= 3.104, 
p<0.02), LFD without BB (t8= 2.793, p<0.05), and HFD with BB (t8= 3.416, p<0.008), while it 
decreased NF-kB levels in mice on a LFD with BB (t8= 2.956, p<0.008). BB supplementation 
significantly reduced NF-kB levels in mice on a LFD compared to the LFD without BB group after 
Mn treatment (t8= 3.844, p<0.006).
4.4.8 A HFD Resulted in Neuronal Loss in the Substantia Nigra
4.4.8.1 Nissl Staining
A significant main diet effect (Table 4.1 and Fig. 4.5A and 4.5C) was found on the total number 
of neurons estimated through Nissl staining in the substantia nigra pars compacta (SNPc) region 
of the mid brain. No significant interaction effects were found. The HFD vehicle group had 
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significantly smaller numbers of stained neurons compared to the NFD (t8= 3.401, p<0.03) vehicle 
group. After Mn administration, the HFD group showed a significant reduction in number of cells 
compared to the NFD (t8= 3.791, p<0.007) and the LFD (t8= 4.045, p<0.003) groups. In presence 
of vehicle, HFD with BB group was also significantly different from LFD with BB group (t«= 
3.733, p<0.008).
4.4.8.2 TH Staining
A significant main diet effect (Table 4.1 and Fig. 4.5B and 4.5D) was found for the total number 
of dopaminergic neurons assessed through tyrosine hydroxylase staining in the substantia nigra 
pars compacta (SNPc) region. No significant interaction effects were found. Overall, the HFD 
groups tended to have smaller numbers of TH positive neurons in the SNPc compared to the NFD 
and LFD groups. The HFD vehicle group had a significant smaller number of TH neurons 
compared to NFD vehicle group (t«= 3.106, p<0.05). Moreover, HFD with BB vehicle group had 
lesser number of neurons compared to NFD vehicle groups (t8= 3.376, p<0.03).
4.5 Discussion
Results from our study reveals that endemic Alaskan BB consumption significantly improved 
anxiety-like (open field), motor coordination (parallel rod floor test), sensory (cylinder test) and 
cognitive (novel object recognition) behaviors for mice on a LFD and NFD diet when introduced 
to neurotoxic challenge with Mn. Among all the diet groups, mice fed on HFD performed the least 
in all behavioral tasks. These animals were more anxiogenic and had impaired memory, sensory 
and motor co-ordination possibly due to metabolic burden as examined by others (34, 35). Mn 
treatment triggered reduced locomotor, memory and motor functions in tested behaviors for all the 
three diet groups and this effect was most pronounced in mice fed on HFD. Interestingly, Mn 
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treated HFD animals that consumed BB performed better in parallel rod floor (motor coordination) 
and cylinder test (sensory motor) when compared to HFD animals that were not fed with BB but 
received Mn insult. This suggests that when combined with toxic insult HFD can dampen the 
beneficial effect of BB. We also observed that BB was not able to reverse the memory impairment 
in the HFD animals as shown by Carey and colleagues (7) who used a temperate species of BB: 
Vaccinium ashei for their experiments. As mentioned earlier, the polyphenolic profile of Alaskan 
BB largely varies from the non-arctic species (18). This difference in result could have resulted 
from using a different Vaccinum sp. growing under the influence of varying environmental 
conditions and thereby having alternative anthocyanin content.
BDNF is abundant in brain regions that modulate neuroplasticity underlying learning and 
memory (36). The hippocampus serves as an important hub for controlling memory acquisition, 
storage and retrieval (37). Prior studies have indicated that the levels of BDNF in the hippocampus 
directly correlate to performance in memory tasks for rodents (7, 35). There is also evidence that 
obesity triggered by diet can lead to memory impairments in adult rodents (38). Furthermore, 
polyphenols are shown to enhance cognition by regulating extracellular signal-regulated kinase 
pathways (39). In our study, BB improved the BDNF levels either in combination with NFD or 
LFD. However, this effect was dependent on the diet of the animals and the type of treatments they 
received (Mn or Vehicle). These results show a novel interaction where a certain diet (NFD) in 
combination with a supplement (BB) can be beneficial in the normal physiological state. The same 
supplement (BB) when combined with a different diet formulation (LFD) can improve molecular 
markers in a neurotoxic condition. Consumption of a HFD has been linked with reduced BDNF 
levels in the cortex and hippocampus of rodent brains (17, 40). Contrary to prior investigations 
which have revealed elevated BDNF levels in presence of BB and a HFD (7), we found increased 
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BDNF in the hippocampus of animals fed with BB and LFD. This is not surprising since the 
mechanistic action of BB is linked to the complex interactions between BB anthocyanins with 
molecular pathway intermediates (7). Because our study utilizes an endemic BB species with a 
very different anthocyanin profile that is largely influenced by environmental conditions, the 
current results corroborates the hypothesis of differential regulation of BDNF. Though, our 
experiments do not investigate any specific BDNF pathway, such complex associations between 
BB polyphenols, BDNF expression coupled with selection of diet type is subjected to further 
scrutiny.
Microglial cells are key players of neuroinflammation and their activation is often associated 
with aging and neuronal dysfunction (41). Such changes further cause nitrosative stress causing 
NOS2 production and elevated levels of the stress-sensitive protein, NF-kB (6). A HFD is notable 
for aggravated expression of microglia and associated factors (42). Previous research elucidates 
the role of blueberries in ameliorating microglial activation and levels of NF-kB in aged mice and 
rats (43). Studies also elaborate on the mechanistic actions of BB in attenuating microglial 
mediated release of nitric oxide (7, 44). Our study showed spikes in microglial and nitrosative 
stress markers (NOS2/iNOS and NF-kB) in the HFD group compared to other diets (7). 
Interestingly, our finding highlights the novel interactions of Alaskan BB with different diets in 
combating neurotoxicity. In the case of Mn treatment, BB in combination with NFD conferred 
protection by reducing only levels of NOS2/iNOS and not NF-kB. On the other hand, BB in 
presence of LFD was beneficial in reducing both NOS2/iNOS and NF-kB and thereby improving 
the neurotoxic pathology. This preventative action of BB on Mn-toxicity was not reflected in the 
HFD group. Expression of NOS2 in response to Mn necessitates the up regulation of NF-kB (6). 
Research also shows mechanisms of NO expression occurring independent of NF-kB activation
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(45). However, it is unknown whether such independent actions occur during Mn-induced 
neurotoxicity.
Dysregulation of the neuronal function due to a disease pathology can result in synaptic loss, 
impaired signaling and progressive change of neuronal structures (46). These transitions often 
occur before the actual neuronal cell loss or cell death in chronic neurodegenerative diseases (46). 
Mn vulnerability is often linked with changes in cytoskeletal structures which cause damage to the 
neuronal circuits in the long axons of the dopaminergic neurons of the SN (4). The 
neuropathological alterations observed with such exposure also indicate that Mn toxicity is not just 
restricted to dopaminergic neurons in the SN, but also can occur in the globus pallidus and striatum 
(4, 47) . Few studies with rare human post mortem tissue samples also show that modified 
morphology resulting from excessive environmental exposure of Mn treatment can vary from no 
obvious changes to massive atrophy of neurons and glial structures in brain regions (47). This 
could possibly explain our results which demonstrated no differences in total cell number / TH 
positive neurons between the manganese and vehicle treated NFD and LFD groups in the SN 
region. Furthermore, only HFD group showed significant loss of neurons in comparisons with the 
other diet groups. Studies have suggested that HFD can possibly lead to dysfunction of dopamine 
and opioid neurotransmitter systems and related variations in gene expression level (48). The 
animals for this study were euthanized for brain sample collection within a 7-10 day of the sub-
chronic Mn administration. Hence, the experimental period post exposure may be enough to 
present remarkable modifications in behaviors, biochemical markers and possibly neurite length 
structure rather than complete neuronal loss. Though there has been research to characterize the 
dosage and neurotoxicity of Mn (49, 50), little work has been done to study the interaction of diet 
and environmental toxins. Further research should target investigating the neuronal structure 
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changes occurring due to different diets. Future investigations should focus on whether such 
cytoskeletal changes are limited to neurite structure or causing overall circuit level disruption. Our 
study can form the basis for such future exploration.
In summary, our study illustrates a complex interaction between dietary fat and BB in 
ameliorating metal induced neurotoxicity and concomitant behavioral correlates. The data 
reiterates the deleterious effects of consuming HFD bolstering the evidence that associate 
metabolic overload and neurotoxic pathophysiology. Importantly, it reflects that consuming HFD 
and or obesity can mask the positive health promoting effects of BB supplementation, showing 
that a change of diet and loss of weight is imperative for health and supplements alone cannot 
mitigate the effects of HFD and obesity.
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4. 7 Figures and Tables
Figure 4.1 Study Design.
3 month old male C56/BL7 mice were fed on Normal fat diet (NFD), Low fat diet (LFD) and High 
fat diet (HFD) for 4 months in presence or absence of Alaskan blueberry (BB). All experimental 
animals were then administered single subcutaneous injections of 0 mg/kg or 50 mg/kg MnCl2 (in 
saline) on 1, 3 and 5th day. Following which the animals were tested for open field (OF), object 
recognition (OR), cylinder test (CT) and parallel rod floor (PR) test. After the last behavioral 
assays, the animals were euthanized, and brain samples were collected for the biochemical 
experiments.
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Figure 4.2 Alaskan Blueberry Supplementation Enhanced Locomotor, Anxiety and Memory 
Functions in Mice on a LFD
(A) Locomotor activity in open field test was measured as the total distance travelled in the open 
field test, (B) anxiogenic behavior was assessed as the number of central entries in the open field 
test and (C) memory function was measured as the recognition index in the object recognition test. 
* p<0.05, ** p<0.01 and *** p<0.001 represents significant differences between vehicle and Mn 
treated or BB and non BB treated groups. 1, 2, 3 and 4 represents significant difference between 
HFD with other diet groups in vehicle condition, 6, 7 and 8 represents significant difference 
between HFD with other diet groups in MnCl2 condition (where 1 = NFD, 2/6 = NFD + BB, 3/7 = 
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LFD and 4/8 = LFD + BB) (n=12-13 animals per group, p<0.05, Bonferroni multiple comparison 
test).
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Figure 4.3 Alaskan Blueberry Supplementation Ameliorates Mn-induced Sensory and Motor Co-
ordination Deficits in Mice Consuming NFD and LFD
(A) Sensory function was assessed by measuring 'number of rears' in the cylinder test and (B) 
motor co-ordination was measured in form of 'ataxia index' in parallel rod floor test. * p<0.05, ** 
p<0.01 and *** p<0.001 represents significant differences between vehicle and Mn treated or BB 
and non BB treated groups. 1, 2, 3 and 4 represents significant difference between HFD with other 
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diet groups in vehicle condition, 6 and 8 represents significant difference between HFD with other 
diet groups in MnCl2 condition (where 1 = NFD, 2/6 = NFD + BB, 3 = LFD and 4/8 = LFD + BB) 
(n=12-13 animals per group, p<0.05, Bonferroni multiple comparison test).
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Figure 4.4 Alaskan Blueberry Improves Hippocampal BDNF and Attenuates Levels of 
Inflammatory Markers in the SN Region 
(A) Brain homogenates from hippocampus were measured using ELISA for BDNF levels. Brain 
homogenates from substantia nigra region were measured using ELISA for (B) iba1 levels (C) 
NOS2 levels and (D) NF-KB levels. * p<0.05, ** p<0.01 and *** p<0.001 represents significant 
differences between vehicle and Mn treated or BB and non BB treated groups. 1, 2, 3 and 4 
represents significant difference between HFD with other diet groups in vehicle condition; 6, 7 
and 8 represents significant difference between HFD with other diet groups in MnCl2 condition 
(where 1 = NFD, 2/6 = NFD+ BB, 3/7 = LFD and 4/8 = LFD+ BB) (n=5 animals per group, 
p<0.05, Bonferroni multiple comparison test).
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Figure 4.5 HFD Consumption Decreases Total Cell Count and Tyrosine Hydroxylase
Immunoreactive Neurons in the SN region 
(A) Bright field images of Nissl staining of coronal brain sections in the SNPc region of the mid 
brain area. Scale bar 200μm. (B) Bright field images of DAB-TH staining of coronal brain sections 
in the SNPc region of the mid brain area. Scale bar 200μm. (C) Graphical representation revealed 
the significant effect of HFD on reduced cell counts in the SNPc region of the mid brain, 1, 3 and 
4 represents significant diet differences from NFD, LFD and LFD + BB respectively (n=5, p<0.05, 
Bonferroni multiple comparison test). (D) Graphical representation revealed the significant effect 
of HFD on reduced TH immunoreactivity in the SNPc region of the mid brain. 1 represents 
significant differences from NFD (n=4-5, p<0.05, Bonferroni multiple comparison test).
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Tables
Table 4.1 Summary of Statistical Effects of Individual Factors (Diet, BB and MnCl2 treatment) 
and their Interactions on Behavioral and Molecular Measures used in the Study
Measure Diet effect Blueberry effect Mn treatment
effect
Interaction
effect
Total distance F2,137 = 49.86, F1,137 = 11.76, F1,137 = 32.41, Diet and BB
p<0.001 p<0.0009 p<0.0001
F2,137 = 3.85,
p<0.03
Central entries F1,141= 90.72, F1,141 = 36.44, F1,141 = 55.95, Diet and Mn
p<0.001 p<0.001 p<0.001
F1,141 = 30.45,
p<0.001
Diet and BB
F1,141 = 6.04,
p<0.02
Recognition F1,141 = 58.35, F1,141 = 32.42, F1,141 = 30.10, BB and Mn
index p<0.0001 p<0.0001 p<0.0001
F 1,141 = 13.01,
p<0.0005
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Rears F1,141 = 41.75,
p<0.0001
F1,141 = 6.81,
p<0.02
F1,141 = 66.65,
p<0.0001
BB and Mn
F1,141 = 6.76,
p<0.02
Ataxia F1,141 = 54.97, F1,141 = 14.98, F1,141 = 68.04, Diet and Mn
p<0.0001 p<0.0003 p<0.0001
F1,141 = 5.15,
p<0.03
BB and Mn
F1,141 = 20.83,
p<0.0001
bdnf F1,52 = 26.10, F1,52 = 12.70, F1,52 = 10.20, -
p<0.0001 p<0.0009 p<0.003
IBA1 - F1,48 = 6.83, F1,48 = 11.28, BB and Mn F1,48
p<0.02 p<0.002 = 11.21, p<0.002
Diet and BB F1,48
= 16.26,
p<0.0001
NOS2 - F1,52 = 10.36, - -
p<0.003
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NfkB F1,52 = 5.35,
p<0.03
F1,52 = 5.75,
p<0.03
Total cells F1,52 = 41.53, - - -
p<0.0001
TH F1,52 = 18.55, - - -
immunoreactivit p<0.0001
y
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Table 4.2 Diet Composition.
% Kcal from 10 Kcal% fat 
diet (Low-fat 
diet)
60 Kcal% fat 
diet (High-fat 
diet)
Protein 20.5 18.4
carbohydrate 69.1 21.3
Fat (Lard) 10.4 60.3
Kcal/g 3.6 5.1
The diet composition in the study has been used as per Carey et al. (2014). The Alaska blueberries 
were added to the pellet at 5% of the pellet weight. The pellets were prepared by PMI Nutrition 
International, St. Louis, MO, (http://www.labdiet.com/Products/CertifiedDiets/).
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Chapter 5: General Conclusions
5.1 General Overview
Neurodegenerative disorders, such as Parkinson's disease (PD), are debilitating disorders 
affecting an increasing number of populations throughout the world [1]. The exact etiology is 
unknown and several molecular factors like oxidative stress, inflammation, mitochondrial 
dysfunction, α-synuclein aggregation and cell death have been reported to be associated with PD 
pathology [2]. Environmental influences, such as diet, play a major role in influencing the 
progressive pathophysiology [3]. The treatment options in PD are limited and most of the 
translational research often fails to reach the further stages of drug development [4, 5]. Plant- 
derived natural products have been tested extensively in in vitro and in vivo models for treatment 
of this chronic neurodegenerative disorder [6]. Nonetheless, the interplay between natural therapy 
and external factors, such as diet, in addressing this complex diseased condition has been rarely 
explored. Moreover, either the mechanistic approach for the treatment options remains 
understudied or the treatment itself lacks reproducibility in different physiological systems. 
Furthermore, absence of a single animal model to reflect complete pathogenesis and progressive 
nature of PD creates hindrance in determining an exact disease modifying therapy [7]. Through 
this thesis, I examined the effect of natural therapy, diet (specifically fat levels) and underlying 
molecular mechanisms of neurodegenerative pathologies in two animal models: Caenorhabditis 
elegans and Mus musculus.
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5.2 Effect of Alaskan Bog Blueberry on α-synuclein Overexpression in a Transgenic 
Model of Caenorhabditis elegans.
In the experiments described in Chapter 2, we tested the effects of indigenous Alaskan bog 
blueberry (BB) on α-synuclein overexpression in a transgenic model of Caenorhabditis elegans 
(C. elegans). Previous research from our laboratories reported that endemic Alaskan botanicals, 
including BB, had anti-ageing and anti-inflammatory effects in in vitro and in C. elegans [8, 9]. 
Our study further examined the role of the BB polyphenols in the context of protein misfolding. 
We for the first time, reported that BB polyphenols reduced expression of the toxic protein a- 
synuclein and improved movement deficit in the nematode model of C. elegans [10]. It was also 
observed that specific anthocyanins and proanthocyanidins fractions were the key polyphenolic 
compounds mediating this beneficial outcome. Furthermore, our data revealed the novel molecular 
mechanism through which BB inhibits Sirtuin 1, a key molecular target and relives protein 
overexpression. The results from this research enhance the knowledge of the use of indigenous 
botanicals as alternative medicine for neurodegenerative disorders. As a continuation to the study, 
it would be interesting to characterize the chemical composition of berry extracts and identify 
which specific molecule(s) contribute to such neuroprotective pathways leading to future 
translational research.
5.3 Silencing Fat Metabolism Genes in Parkinson's like Models of Caenorhabditis elegans.
Through Chapter 3, we evaluated the role of fat metabolism on key features of PD-like 
pathology such as α-synuclein overexpression (both wild-type and A53T mutation) and 
environmental toxin-induced dopaminergic neuron degeneration in models of C. elegans. Fat 
metabolism in general is known to impact longevity [11, 12] and stress response pathways 
mediated through insulin signaling [13]. Besides, delaying aging by modulating insulin signaling 
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has been implicated to be profitable in PD-like models of C. elegans [14]. There have been no 
studies conducted so far to examine the relationship between fat metabolism and PD-like 
pathology in nematode models. Through RNA interference (rather than diet), we genetically 
manipulated the nematodes to create high and low fat levels in the organisms. We found that low 
fat content due to silencing of fat-5 and fat-7 genes was most beneficial in reducing the α-synuclein 
expression, rescuing DA neuron degeneration and improving DA-dependent behaviors. 
Interestingly, the high fat content due to genetic silencing of nhr-49 and tub-1 genes had no 
significant effect on any of the PD-like molecular features in the worm models. Our results also 
demonstrated no alteration in lifespan of the transgenic PD models on silencing of these candidate 
genes suggesting decoupling between longevity and general health. Overall, our data highlighted 
the beneficial effect of low fat diet in ameliorating PD-like symptoms in models of C. elegans. In 
the current research, we did not examine the different fat molecules and the downstream molecular 
targets that could be responsible for this profitable effect. These questions can be further addressed 
in follow up studies.
5.4 Complex Interaction of Dietary Fat and Alaskan Bog Blueberry Supplementation Influences 
Manganese Mediated Neurotoxicity and Behavioral Impairments.
Finally, in Chapter 4, we investigated the combined role of dietary fat (normal, low and 
high fat) and supplementation (in form of Alaskan BB) on the neuronal health and behavioral 
outcomes in a manganese-induced neurotoxic model of Mus musculus (mice). Previous studies 
have highlighted the anti-oxidant and anti-inflammatory role of BB in combating features of the 
ageing brain (such as memory loss, protein aggregation etc.) [15-21]. Recent research also 
elucidates the role of high fat diet and blueberry supplementation in improving neural plasticity in 
aging mice [22, 23]. Moreover, obesity is considered a risk factor for PD [3], but there have been 
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conflicting data reporting the same. Our study is the first to compare different diets in combination 
with Alaskan BB on neurotoxic end points in a metal induced mice model, which presents clinical 
features also seen in PD. Here, we reported that overall a low fat diet was neuroprotective and in 
the presence of BB it improved behavioral phenotypes (locomotion, memory and motor co­
ordination) and molecular markers (inflammatory IBA1, NF-KB, NOS2/iNOS and neurotrophic 
growth factor BDNF). However, we did not find any major differences in number of dopaminergic 
neurons between the control and MnCl2 treated groups. We speculate that considering the 
experimental time frame, MnCl2 exposure was not enough to cause complete cell loss. Probably, 
the exposure to MnCl2 induced neurotoxic conditions and led to changes in neuronal morphology 
and probably cytoskeletal structures as well. This was not addressed in our current research and 
requires future investigations. On the contrary, and supporting our hypothesis, a high fat diet 
compared to other treatments was found to be deleterious in inducing a pro-inflammatory response, 
worsening behaviors and triggering dopaminergic cell loss in the mouse model supporting our 
hypothesis. The results from this chapter further bolstered the association between PD and obesity 
and substantiated our understanding that the benefit of supplements, such as BB, cannot overcome 
the detrimental effects of a high fat diet. This further reiterates the importance of consuming a 
balanced diet with low fat content along with therapeutic interventions for ensuring treatment 
success in progressive disorders like PD.
5.5 Overall conclusion
Our results demonstrated for the first time the effect of culturally relevant Alaskan 
botanical in displaying protection against neurodegeneration in two different in vivo model 
systems. Importantly, the studies showed how neurodegenerative pathology can be modulated by 
fat content either genetically (e.g., RNAi of fat metabolism) or through dietary interventions (e.g., 
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feeding different ‘fat diets'). We also uncovered novel underlying mechanistic approaches 
influenced by consumption of Alaskan bog blueberry. Different cellular symptoms, such as protein 
overexpression and neuronal morphology, and molecular markers, such as inflammation and 
neurotrophic growth factors, were affected by external environmental factors, i.e., diet and 
supplementation, or intrinsic processes, i.e., aging and neurodegenerative physiology. This 
supports the explanation that a reciprocity between multiple factors and genetic mechanisms is 
what fosters health-promoting benefits of therapeutic inventions. Lastly, use of subsistence species 
like Alaskan BB as potential treatment recapitulates the traditional knowledge on consuming the 
endemic plants and further deciphers the molecular pathways underlying aging and 
neurodegeneration process.
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